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The hepatitis B virus (HBV) was discovered by dr. Baruch Samuel Blumberg when he 
identified the ‘Australia antigen’ among an aboriginal in the 1960s. The ‘Australia antigen’ 
is nowadays known as the hepatitis B surface antigen (HBsAg). For his work dr. Blumberg 
was awarded the 1976 Nobel Prize in Medicine. Despite the introduction of safe and ef-
fective vaccines in the eighties, HBV infection still constitutes a major burden of disease. 
Currently, about one third of the world’s population has evidence of past or current HBV 
infection and over 350 million people still being chronically infected.1 Approximately 
45% of the infected population lives in high endemic areas (HBV prevalence over 8%) 
including Asia and sub-Saharan Africa. Chronic HBV infection remains one of the most 
serious infectious diseases worldwide with 0.5-1.2 million deaths every year due to long-
term sequelae of hepatitis B related chronic liver disease, such as liver cirrhosis, hepatic 
decompensation and hepatocellular carcinoma (HCC).2
tHe HePAtItIs B vIrus
The HBV is one of the smallest enveloped animal double-stranded DNA viruses (virion 
diameter 40-42 nm) belonging to the family of the Hepadnaviridae, which have a strong 
preference for infecting hepatocytes.3,4
The virus particle (virion) consists of an outer lipoprotein envelope containing HBsAg. 
The hepatitis B core (HBcAg) is located within this outer layer and contains the viral 
genome and HBV DNA polymerase, which is necessary for viral synthesis. Analysis of the 
nucleotide sequence of the virus revealed four overlapping open reading frames (ORFs), 
regions of the genome which may code for viral antigens.4 The surface (S) ORF encodes 
the envelope protein, which consists of three separate surface proteins: large (L), middle 
(M), and small (S) proteins. The polymerase (P) ORF encodes a multifunctional protein 
that is involved in encapsidation, initiation of minus strand DNA synthesis, reverse tran-
scription, and degradation of pre-genomic RNA. The core (C) ORF encodes both HBcAg, 
which is a structural nucleocapsid core protein, and hepatitis B e antigen (HBeAg), which 
is a soluble nucleocapsid protein. The X ORF encodes hepatitis B x protein (HBx), which 
plays roles in signal transduction, transcriptional activation, DNA repair, and inhibition 
of protein degradation.5
After entry in the hepatocyte, the HBV is converted to covalently closed circular DNA 
(cccDNA) in the hepatocyte nucleus. The cccDNA forms the key template for transcrip-
tion of both messenger RNA (for translation of viral proteins), as well as pre-genomic 
RNA (for reverse transcriptase into genomic DNA). The formed particle can either be 
excreted via the Golgi apparatus or recycled into the nucleus to form cccDNA.3 Be-
cause the cccDNA is highly resistant to antiviral therapy and the host’s immunological 
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response, complete eradication of HBV from the liver is not yet feasible.6 The HBV is 
divided into eight genotypes (A-H) according to overall nucleotide sequence variation 
of the genome. The genotypes have a distinct geographical distribution and this has 
been associated with anthropological history, with genotypes A and D as African and/or 
Caucasian and B and C as South-East Asian genotypes.7
PHAses of INfeCtIoN
Infection with HBV can lead to acute hepatitis which can either resolve spontaneously, 
become chronic or result into a fulminant hepatitis with decompensated liver cirrhosis. 
The risk of developing chronic hepatitis B (CHB) depends on the age of the subject 
at time of infection. Perinatal infection from the infected mother to the child in high 
endemic countries results in CHB in an estimated 90%, whereas infection with HBV in 
adults with a mature immune system - mainly through sexual contacts or by (sharing) 
needles - results into chronic disease in only 5%.7,8 CHB is characterized by HBsAg posi-
tivity for at least six months. Patients with CHB may present in any of four, not necessarily 
sequential, phases of infection, depending on the presence of HBeAg with/without its 
antibody anti-HBe and serum levels of HBV DNA and alanine aminotransferase (ALT).7,9
table 1. Phases of chronic hepatitis B infection
Phase HBeAg HBv DNA (Iu/mL) ALt
Immune tolerance Positive >200.000 Normal
Immune clearance Positive >20.000 Elevated
Inactive carrier Negative < 2000 Normal
HBeAg negative CHB Negative Fluctuating Fluctuating
During the immunotolerant phase (1), which is common among perinatally infected 
patients, the virus is not recognized by the host-immune system, resulting in a high 
serum HBV DNA and HBsAg with a detectable HBeAg, while the serum ALT concentra-
tion is within normal range and liver histology shows minimal inflammation. In the 
immuno-active phase (2), the host immune response results in a decline in HBV DNA and 
HBsAg level. During this phase HBeAg loss and seroconversion to antibodies to HBeAg 
(anti-HBe) may occur. However, prolonged hepatic inflammation (as measured by high 
ALT levels) in this phase is an indication for starting antiviral therapy to reduce the risk 
of disease progression.9,10 HBeAg seroconversion is often followed by the inactive car-
rier state (3), further characterized by a low serum HBV DNA level (<2000 IU/mL) and 
normalization of ALT. HBsAg also declines further in this state. However, in a significant 
proportion of HBeAg negative patients viral replication recurs or persists at higher lev-
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els, resulting in HBeAg negative active CHB (4). This phase of infection develops through 
presence of viral strains harbouring mutations in the precore or basal core promotor 
region that reduce or abolish the expression of HBeAg. Yet, since both HBV DNA and ALT 
can fluctuate in this phase, distinction from ‘inactive carriers’ can be difficult, indicating 
the importance of serial measurements of HBV DNA and ALT, and perhaps also HBsAg, 
to identify those patients who require treatment.
treAtmeNt goALs
The ultimate goal of anti-HBV treatment in order to prevent the development of long-term 
sequelae of chronic liver disease is to completely eradicate the HBV from host hepatocytes.11 
However, with the currently available agents this cannot be achieved due to persistence 
of HBV cccDNA in the liver.12 Therefore, surrogate outcomes are used as measurements of 
therapy efficacy and success. Several independent studies have shown that lower levels of 
HBV DNA and HBsAg, as well as clearance of HBeAg are associated with a lower risk of HBV 
related chronic liver disease.13-15 Major endpoints of treatment are therefore, 1) reduction of 
HBV DNA to undetectable levels (virologic response), 2) loss of HBeAg with or without anti-
HBe (serologic response), 3) normalization of ALT levels (biochemical response) and 4) a 
reduction in necroinflammation with or without improvement of liver histology (histologic 
response).10 Although rarely achieved, loss of HBsAg from serum, accompanied by appear-
ance of anti-HBs, is currently considered closest endpoint to clinical cure of disease.16
treAtmeNt oPtIoNs
Currently approved agents include the immune modulating (peg)interferon ((PEG)-IFN) 
and five viral polymerase inhibiting nucleos(t)ide analogues (NA). Treatment efficacy is 
evaluated differently as they have different modes of action.
Interferon therapy
Interferon (IFN) alfa has been a continued therapeutic option since it was licensed in 
the early 1990s for the treatment of CHB. IFN largely acts through enhancement of the 
immunological response of the host against the virus, although there is also a limited 
direct antiviral effect on HBV replication.17 IFN based therapy improved significantly 
by pegylation of interferon (PEG-IFN) which allowed a more convenient once-weekly 
dosing interval, with treatment efficacy equal or superior to conventional IFN. Finite 
treatment (one year) with PEG-IFN injections aims to achieve sustained off-treatment re-
mission of HBV. In HBeAg positive patients the use of a combined serologic and virologic 
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endpoint (HBeAg loss or seroconversion with concomitant HBV DNA < 2,000 IU/mL) is 
preferred, since this endpoint is associated with a low probability of relapse18, a reduc-
tion in risk of HCC development14,19 and a higher probability of subsequent HBsAg loss 
and seroconversion.20 In HBeAg negative patients, prolonged suppression of HBV DNA 
to levels below 2,000 IU/mL combined with ALT normalization is currently considered 
the optimal definition of response to PEG-IFN, although late relapse beyond six months 
post-treatment has been described.9
Furthermore, it has recently been shown that a decline in serum HBsAg after PEG-IFN 
treatment reflects the induction of an effective anti-HBV immune response, possibly as 
an indirect marker of intrahepatic cccDNA decline.21-24 Moreover, it has been shown that 
HBsAg expression in the liver evolves significantly after PEG-IFN therapy.25 However, the 
effect of PEG-IFN on both intrahepatic HBcAg and HBsAg and its relation with serum 
HBsAg has not yet been studied.
Nucleos(t)ide analogue therapy
With the introduction of NA since the late nineties considerable progress has been made 
in the treatment of CHB. NA target the reverse transcriptase of the HBV and are potent 
inhibitors of viral replication. In contrast to IFN therapy, the most important goal of NA-
therapy is on-treatment maintained undetectable HBV DNA level, because persistently 
detectable HBV DNA during therapy is a major risk factor for the development of viral 
breakthrough and progression of liver disease.26,27 While HBeAg seroconversion may her-
ald immune control in untreated patients (spontaneous HBeAg seroconversion) or after 
treatment with (PEG-)IFN, discontinuation after NA induced HBeAg seroconversion is 
associated with a higher probability of post-treatment relapse.28-31 Also in HBeAg nega-
tive patients discontinuation of NA will result in relapse in the vast majority of patients.32 
Therefore, continuation of NA therapy until HBsAg loss or seroconversion seems to be 
the safest. Thus, long-term side effects and costs of NA should also be taken into account 
when initiating such therapy.
oPtImAL fIrst-LINe tHerAPy for CHroNIC HBv-INfeCtIoN
Both PEG-IFN and NA have proven to be effective. However, both treatment options also 
have substantial disadvantages and important limitations. As a result, current guide-
lines9,10 are still lacking clear recommendations as to which treatment strategy should 
be used as first-line therapy.
PEG-IFN may be a valuable option for those patients with a high likelihood of response. 
However, clinical use of PEG-IFN is compromised by the suboptimal tolerability, with 
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a wide spectrum of adverse events, such as flu-like symptoms, emotional lability and 
bone marrow suppression. Furthermore, only a limited number of patients achieve a 
response.33-35 Selection of those patients with the highest probability of response is 
therefore essential for effective use of PEG-IFN in clinical practice. Recently, several stud-
ies have shown that response to PEG-IFN depends upon the infecting HBV genotype, 
baseline levels of HBV DNA and ALT, presence of precore and core promotor mutants 
and IL-28B genotype and previous failure to response to IFN therapy.36-40 Despite these 
important and guiding findings, a reliable prediction of response probabilities for indi-
vidual patients remains challenging.
The most potent NA (entecavir (ETV) and tenofovir (TDF)) are generally recognized 
as first line treatment options, and may induce and maintain undetectable levels of 
HBV DNA in nearly all patients with limited safety concerns and low rates of antiviral 
resistance through up to five years of treatment.41-44 ETV and TDF may also improve his-
tological response and result in a better overall clinical outcome in successfully treated 
patients.45-47 Moreover, it has been shown in Asian patients that successful treatment 
with ETV decreases the chance of HCC development.48
However, the residual risk of HCC necessitates intensive on-going follow-up of patients 
with successfully suppressed viral replication.9 Therapy for decades or possibly even life-
long will be necessary in most patients as high relapse rates have been observed after 
discontinuation of therapy. Moreover, long-term outcomes regarding viral resistance, 
also in relation to compliance to therapy, are unknown.28-31
Development of antiviral resistance of the first NA has been shown to be a major limita-
tion, leading to reversion of virologic and histological improvement and enhancement 
of the rate of disease progression.49 One of the first manifestations of antiviral resistance 
is a virologic breakthrough which is defined as a > 1 log10 increase in serum HBV DNA 
from nadir during treatment in a patient who had an initial virologic response. It is usu-
ally followed by a biochemical breakthrough with elevated levels of serum ALT.
This thesis contains studies describing how to optimize treatment of CHB. The aims of 
this thesis were therefore to:
1. Determine the effect of PEG-IFN therapy on intrahepatic HBcAg and HBsAg expres-
sion in correlation to on-treatment serum HBsAg decline.
2. Identify whether IFN-related factors can help to predict response to PEG-IFN therapy.
3. Explore the long-term efficacy and safety of NA therapy in a large European real-life 
cohort of CHB patients. We studied in particular the occurrence of HCC and ALT flares 
among long-term NA therapy.
4. To evaluate the effect of NA treatment (non-)compliance on treatment outcome.
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Chap ter 1 
Loss of intrahepatic HBsAg expression 
predicts sustained response to 
peginterferon and is reflected by 
pronounced serum HBsAg decline
P. Arends, V. Rijckborst, P.E. Zondervan, E. Buster, Y. Cakaloglu, P. Ferenci, F. Tabak, 
U.S. Akarca, K. Simon, M.J. Sonneveld, B.E. Hansen, H.L.A. Janssen
Journal of Viral Hepatitis 2014 Jan 20, Epub ahead of print
20 Chapter 1
ABstrACt
Background
There is a lack of knowledge regarding the effect of peginterferon (PEG-IFN) on the 
expression of intrahepatic hepatitis B core and surface antigen (HBcAg and HBsAg) in 
chronic hepatitis B (CHB) and its relation with response to therapy.
methods
Fifty-two HBeAg positive and 67 HBeAg negative CHB patients with paired liver biopsies 
taken at baseline and after 1 year of PEG-IFN therapy were studied.
results
After PEG-IFN therapy, HBeAg negative patients showed a significant reduction in both 
intrahepatic HBcAg (p=0.04) and HBsAg expression (p<0.001). In contrast, a reduction 
in intrahepatic HBcAg expression was not observed in HBeAg positive patients, while a 
trend in reduction of intrahepatic HBsAg staining was found (p=0.09). Post treatment, 
7 (13%) HBeAg positive and 9 (14%) HBeAg negative patients had no expression of 
intrahepatic HBsAg. Patients without any intrahepatic HBsAg expression post treatment 
were more likely to achieve a combined response (HBeAg loss with HBV DNA < 2,000IU/
mL for HBeAg positive and HBV DNA <2,000IU/mL and normal ALT for HBeAg negative 
CHB): 71% vs. 5% for HBeAg positive (p<0.001) and 60% vs. 16% for HBeAg negative 
patients (p=0.004), respectively. Moreover, a more profound decline of serum HBsAg 
was observed in patients with absence of intrahepatic HBsAg staining (3.1 vs. 0.4 log 
IU/mL, p<0.001 and 1.7 vs. 0.4 logIU/mL, p=0.005 for HBeAg positive and negative CHB, 
respectively).
Conclusion
PEG-IFN reduces expression of intrahepatic HBsAg. Loss of HBsAg as assessed by im-
munohistochemistry from the liver predicts a sustained response, and is reflected in a 
pronounced serum HBsAg decline.
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INtroDuCtIoN
Chronic hepatitis B (CHB) remains a major health problem affecting 350-400 million people 
worldwide and causing one million deaths every year.1 To prevent progression of liver dis-
ease to cirrhosis, liver failure and hepatocellular carcinoma antiviral therapy reducing viral 
replication is indicated in a large proportion of patients with both hepatitis B e antigen 
(HBeAg) positive and negative CHB.2 Both nucleos(t)ide analogues (NA) and peginterferon 
(PEG-IFN) have been shown to reduce viral replication. However, unlike NA, PEG-IFN does 
not only have a direct antiviral effect, but also stimulates the induction of a host immune 
response against the hepatitis B virus (HBV). An effective immune response may conse-
quently result in a decrease in intrahepatic covalently closed circular DNA (cccDNA), which 
plays a major role in viral persistence.3-5 With the introduction of quantitative assays for 
serum hepatitis B surface antigen (HBsAg) it has been shown that serum HBsAg levels 
may reflect intrahepatic cccDNA.6 Recent studies have shown that serum HBsAg levels 
are higher in HBeAg positive compared to HBeAg negative patients.7,8 Furthermore, it has 
been shown that a decline in serum HBsAg after PEG-IFN treatment reflects the induction 
of an effective anti-HBV immune response, possibly through an association with intrahe-
patic cccDNA decline.9-13 However, the exact mode of action remains unclear.
Immunodetection of HBsAg and hepatitis B core antigen (HBcAg) in hepatocytes 
provides helpful information concerning the replicative status of the hepatitis B virus 
and is usually performed as part of a histopathological assessment of CHB patients.14 
Intrahepatic HBsAg can be detected by immunohistochemistry in liver tissue of both 
asymptomatic HBV carriers and in patients with chronic active hepatitis B. Expression of 
HBcAg in hepatocyte nuclei, detected by immunohistochemical techniques, correlates 
with the level of viral replication and is generally found in HBeAg positive CHB patients.15 
It has been indicated that there is an association between intrahepatic HBsAg expression 
and serum HBsAg in Asian CHB patients.16,17 Furthermore, baseline intrahepatic HBsAg 
expression appeared to be a predictor for response (i.e. HBeAg loss) to IFN therapy in a 
recent study.16 However, intrahepatic HBsAg and HBcAg expression were not linked to 
other response markers, such as serum HBV DNA, HBsAg and HBeAg decline.
Previous studies have shown that (PEG-)IFN improves liver inflammation and slows progres-
sion of fibrosis.18-22 Moreover, it has recently been shown that HBsAg expression in the liver 
evolves significantly after (PEG-)IFN therapy.16,23 However, the effect of PEG-IFN on both in-
trahepatic HBcAg and HBsAg in a large heterogeneous population has not yet been studied.
The aims of this study were therefore to 1) investigate the association between pre-
treatment intrahepatic expression of HBcAg and HBsAg and response to PEG-IFN 
therapy, 2) to determine the effect of PEG-IFN therapy on intrahepatic HBcAg and 
HBsAg expression and 3) to correlate on-treatment serum HBsAg decline with changes 
in intrahepatic HBsAg expression.
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metHoDs
study population
Patients were enrolled from two randomized controlled trials investigating the efficacy 
of one year of PEG-IFN therapy in HBeAg positive and negative CHB.20,22 Post treatment 
follow-up lasted 6 months. HBeAg positive patients were treated with PEG-IFN with or 
without lamivudine. For the current analysis, only patients treated with PEG-IFN mono-
therapy were included given the difference of on-treatment HBV DNA suppression in 
patients treated with or without lamivudine. HBeAg negative patients were treated with 
PEG-IFN with or without ribavirin. Since ribavirin had no effect on HBV DNA or HBsAg 
decline at and of FU, nor on end of treatment or off-treatment responses, both treat-
ment groups were eligible for this study.9 Both studies were conducted in accordance 
with the guidelines of the Declaration of Helsinki and the principles of Good Clinical 
Practice. All patients gave written informed consent according to standards of the local 
ethics committees.
Liver biopsies
Patients were eligible for the current study if a liver biopsy was available before and 
after PEG-IFN therapy. Baseline biopsies were taken at baseline, or if a recent biopsy 
(taken less than one year before the start of therapy) was available, no new biopsy was 
required. In HBeAg positive patients a second liver biopsy was taken directly post PEG-
IFN therapy (1 year). In HBeAg negative patients a second liver biopsy was taken at the 
end of follow-up (6 months post treatment). All paired biopsies were blinded and scored 
by one experienced liver pathologist (PEZ). The adequacy of biopsy samples was judged 
using its length and the number of portal tracts. Expression of HBcAg and HBsAg in 
hepatocytes was studied by the avidin-biotin immunoperoxidase method.
Immunohistochemical detection of HBsAg and HBcAg was performed according the 
standard procedures using a monoclonal anti-HBs antibody (Neomarkers, Fremont, 
CA, USA) and a polyclonal anti-HBc antibody (Dako, Glostrup, Denmark). The degree 
of intrahepatic HBsAg and HBcAg expression was scored in a systematic way assessing 
the proportion of the immunolabeled cells and ranked on a scale of 0 to 5 (0%, 1-10%, 
11-25%, 26-50%, 51-75% and >75%, respectively). 15 Furthermore, the degree of necro-
inflammation and fibrosis was scored according to the Ishak system which includes a 
necroinflammatory score (0–18) and a fibrosis score (0–6). 24
Laboratory testing
Alanine aminotransferase (ALT) was assessed locally in accordance with standardized 
procedures and therefore expressed as times the upper limit of normal (ULN). Serum 
HBV DNA levels were measured using an in-house developed Taqman polymerase chain 
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reaction (PCR) assay (lower limit of detection 373 copies/ml) based on the Eurohep 
standard or the Cobas TaqMan PCR assays (Roche; lower limit of detection 6 IU/mL). 
Serum HBsAg was quantified using the ARCHITECT HBsAg assay (Abbott laboratories; 
range 0.05-250 IU/mL).
statistical analysis
Serum HBsAg and HBV DNA levels were logarithmically transformed for analysis. 
Comparisons between groups were made using the Chi-2-test and the Mann–Whitney 
test. Differences in degrees of expression of HBcAg and HBsAg in hepatocytes between 
HBeAg negative and positive CHB and before and after therapy were analyzed by the 
Wilcoxon rank sum test. Correlation of levels of HBV DNA, ALT and HBsAg in sera with 
the degrees of expression of HBsAg in hepatocytes was assessed by Pearson correlation. 
Statistical analyses were performed using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA). 
All statistical tests were two-sided and were evaluated at the 0.05 level of significance.
resuLts
One hundred and nineteen CHB patients with paired liver biopsies were included in 
this study (Figure 1). Baseline characteristics for both HBeAg positive and negative CHB 
patients are shown in table 1. Seven HBeAg positive patients (14%) achieved a com-
bined response (HBeAg loss with HBV DNA <2,000 IU/mL) at 6 month post treatment. Of 
HBeAg negative patients, 15 (22%) developed combined response (HBV DNA <2,000 IU/
mL and normal ALT) 6 months post treatment.
Patient characteristics and intrahepatic HBcAg and HBsAg expression
The degree of intrahepatic HBcAg staining was significantly higher in HBeAg positive 
compared to HBeAg negative CHB (p<0.001) (Figure 2A). Only three patients did not 
have visible intrahepatic HBsAg expression at baseline, two HBeAg positive and one 
HBeAg negative patient (p=0.58). The degree of intrahepatic HBsAg expression did 
not differ between HBeAg positive and negative patients. (Figure 2B). Interestingly, the 
degree of pre-treatment intrahepatic HBcAg and HBsAg staining did not correlate with 
serum HBV DNA, HBeAg or HBsAg in either HBeAg positive or negative CHB (all p> 0.11).
Among the HBeAg-positive patients, an intrahepatic HBsAg degree >10% was mostly 
seen in genotype D patients (85%), followed by genotypes A (44%), B (40%) and C (30%) 
(p=0.02); a comparable distribution was observed with serum HBsAg levels at baseline 
(HBV genotypes A/B/C/D=4.6 ± 0.4, 4.4 ± 0.3, 3.5 ± 1.1 and 4.7 ± 0.5 log IU/mL respec-
tively; p<0.001). HBeAg negative patients had predominantly genotype D (81%) and 
baseline intrahepatic HBsAg staining did not differ between HBV genotypes (p=0.21).
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combination treatment with 
lamivudine
figure 1. Study population.
table 1. Patient characteristics
HBeAg positive
N=52
HBeAg negative
N=67 p-value
Age (years) 32 ± 10 41 ± 10 < 0.001
Male (%) 40 (77%) 45 (67%) 0.31
Previous IFN therapy (%) 10 (19%) 8 (12%) 0.31
Genotype (%) < 0.001
A 16 (31%) 7 (10%)
B 5 (10%) 1 (2%)
C 10 (19%) 2 (3%)
D 20 (39%) 54 (81%)
Other 1 (2%) 3 (5%)
ALT (x ULN) 3.7 (2.3-5.3) 2.0 (1.5-4.0) < 0.001
Log HBV DNA (cop/mL) 9.2 ± 0.8 6.8 ± 1.2 < 0.001
Log qHBsAg (IU/mL) 4.4 ± 0.7 3.9 ± 0.5 < 0.001
Liver histology
Necroinflammatory score 5.5 (3.3-7.0) 5.0 (4.0-7.0) 0.77
Fibrosis score 2.0 (1.0-3.0) 2.0 (1.0-3.0) 0.38
Cirrhosis* (%) 3 (6%) 1 (2%) 0.31
No HBsAg expression (%) 2 (4%) 1 (1%) 0.58
No HBcAg expression (%) 28 (54%) 56 (84%) < 0.001
Combined response** 7 (14%) 15 (22%)
Data are represented as mean (± standard deviation) or median (range).  * Ishak fibrosis score 5-6. ** 
Combined response at 6 month posttreatment was defined as HBeAg loss with HBV DNA < 2,000 IU/mL for 
HBeAg positive and HBV DNA <2,000 IU/mL and normal ALT for HBeAg negative CHB.
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effect of Peg-IfN on intrahepatic HBcAg and HBsAg expression
After PEG-IFN therapy intrahepatic HBcAg was not expressed in 65% of HBeAg posi-
tive and 94% of HBeAg negative patients. A significant reduction in intrahepatic HBcAg 
expression was only observed in HBeAg negative patients (p=0.04) (Figure 2A).
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figure 2A. Changes in degree of intrahepatic HBcAg expression in HBeAg positive and negative CHB be-
fore and after peginterferon therapy
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figure 2B. Changes in degree of intrahepatic HBsAg expression in HBeAg positive and negative CHB before 
and after peginterferon therapy
26 Chapter 1
Intrahepatic HBsAg expression was absent in 14% of HBeAg positive and 15% of HBeAg 
negative CHB patients after PEG-IFN treatment. Intrahepatic HBsAg expression signifi -
cantly reduced both in HBeAg positive patients (p=0.09) as well as in HBeAg negative 
patients (p<0.001) (Figure 2B).
relationship between intrahepatic HBcAg and response to Peg-IfN
Baseline degree of intrahepatic HBcAg was not associated with response to PEG-IFN in 
either HBeAg positive CHB, HBeAg negative CHB or the overall population (p>0.5). In 
HBeAg positive patients HBeAg loss was observed in 14 out of 34 patients (41%) who 
cleared intrahepatic HBcAg, and in 4 out of 18 patients (22%) without clearance of HBcAg 
from the liver (p=0.23). Mean serum HBeAg decline was more profound in patients who 
showed a decline in the degree of intrahepatic HBcAg compared to patients without 
a decline in intrahepatic HBcAg (2.0 log IU/mL vs 0.7 log IU/mL, p= 0.03). Patterns of 
intrahepatic HBcAg staining were comparable in patients with a decline in intrahepatic 
HBcAg (p=0.21) as well as in patients who showed a more profound decline in serum 
HBeAg (p=0.07)
figure 3. Response rates for patients with and without intrahepatic HBsAg loss after peginterferon therapy.
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relationship between intrahepatic HBsAg and response to Peg-IfN
Baseline degree of intrahepatic HBsAg was not associated with response to PEG-IFN in 
either HBeAg positive CHB, HBeAg negative CHB or the overall population (p>0.2). Next, 
we studied the association between clearance of HBsAg from the liver and response. At 
6 months post treatment, five out of seven (71%) HBeAg positive patients who cleared 
intrahepatic HBsAg from the liver achieved a combined response versus 2 out of 43 pa-
tients (5%) without clearance of HBsAg from the liver (p<0.001) (Figure 3). These patients 
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figure 4A. Serum HBsAg decline in HBeAg positive patients according to the presence of intrahepatic 
HBsAg loss after peginterferon therapy
0 3 6 9 12 15 18
-2.0
-1.5
-1.0
-0.5
0.0
Intrahepatic HBsAg loss (N=10)
No intrahepatic HBsAg loss (N=57)
Follow-up (months)
p-value 0.005
Therapy
se
ru
m
 H
Bs
Ag
 d
ec
lin
e 
(lo
gI
U/
m
L)
Ch 1 fig 4B.pzf:Data 1 - Tue Jul 15 16:50:08 2014
figure 4B. Serum HBsAg decline in HBeAg negative patients according to the presence of intrahepatic 
HBsAg loss after peginterferon therapy
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also had a more profound serum HBsAg decline (3.1 vs. 0.4 log IU/mL, p=0.03) (Figure 
4A).
At 6 months after treatment, HBsAg expression was absent in 10 (15%) HBeAg negative 
patients, of whom 6 (60%) had a combined response versus 9 (16%) of those who still 
expressed HBsAg intrahepatically (p=0.004) (Figure 3). In line with our findings in HBeAg 
positive patients, those without any intrahepatic HBsAg expression post treatment also 
showed a more profound decline of serum HBsAg (1.7 vs. 0.4 log IU/mL, p=0.005) (Figure 
4B).
response at long-term follow-up and intrahepatic HBsAg expression
Long-term follow-up (LTFU) data (mean 2.8 ± 0.6 years) were available for 35 HBeAg posi-
tive patients. Although the number of patients was limited, a remarkable finding was 
that of 5 patients who cleared intrahepatic HBsAg 4 patients (80%) achieved a combined 
response at LTFU, compared to 6 (20%) of patients without clearance of HBsAg from the 
liver (p=0.02). At LTFU, 2 out 5 (40%) HBeAg positive patients without HBsAg staining 
post treatment achieved HBsAg loss from serum, while HBsAg loss was not observed in 
those without intrahepatic HBsAg clearance (Figure 3).
In the HBeAg negative population LTFU data (mean 2.9 ± 0.3 years) were available for 50 
patients. Of 8 patients without intrahepatic HBsAg expression at week 72, 5 (63%) had 
a combined response at LTFU versus 3 (7%) of those with intrahepatic HBsAg expres-
sion (p=0.001). Two out of six (33%) patients with intrahepatic HBsAg loss also cleared 
HBsAg from serum compared with one out of 15 (7%) without intrahepatic HBsAg loss 
(Figure 3).
DIsCussIoN
This is the first detailed report on HBV immunohistochemistry in a large population of 
both HBeAg positive and negative CHB patients treated with PEG-IFN. Important find-
ings are that a one-year course of PEG-IFN therapy significantly reduced the degree of 
intrahepatic HBsAg expression in the liver. In addition, loss of HBsAg expression after 
PEG-IFN therapy is associated with high rates of durable off-treatment response to 
PEG-IFN, and is reflected by a pronounced decline of HBsAg levels in serum. However, 
intrahepatic expression of HBcAg or HBsAg at baseline is not predictive for response to 
PEG-IFN.
Recently, on-treatment serum HBsAg has been shown to predict response to PEG-IFN 
therapy both in HBeAg positive as well as in HBeAg negative HBV patients.9,10 However, 
the exact course of action remains unclear. In our study we showed that PEG-IFN therapy 
reduces the expression of intrahepatic HBsAg in HBeAg negative CHB and appears to do 
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so in HBeAg positive patients. The importance of a reduction of HBsAg expression in the 
liver after PEG-IFN therapy was emphasized by our finding that the absence of HBsAg 
expression in hepatocytes after PEG-IFN treatment was associated with high rates of 
sustained response. Furthermore, patients without intrahepatic HBsAg expression expe-
rienced a strong serum HBsAg decline and were more likely to clear HBsAg from serum 
during LTFU. These results clarify the association between serum HBsAg after PEG-IFN 
and sustained response by its relation with intrahepatic HBsAg staining.
Our results confirm the findings of Takkenberg et al. who showed that in a group of 
24 HBeAg negative patients the mean proportion of hepatocytes that were positive for 
HBsAg reduced after PEG-IFN, but also did not find a significant reduction in 16 HBeAg 
positive patients.23 Intrahepatic HBsAg expression also reduced in 45 interferon treated 
HBV patients.16 However, in contrast to this study from Taiwan and a recent study from 
Thompson et al. we could not find a correlation between serum HBsAg or HBV DNA and 
intrahepatic HBsAg expression in either HBeAg positive or negative CHB at baseline.16,17 
These contradictory results may be explained by the fact that their population mainly 
consisted of Asian patients, infected with genotypes B and C, whereas our cohorts 
mainly consisted of Caucasians infected with genotypes A and D. It has previously been 
shown that the influence of HBV genotype on HBsAg levels both in serum as well as 
intrahepatically may be of significant importance; the highest HBsAg levels have been 
observed for genotypes A and D, compared to lower HBsAg levels in genotypes B and 
C.7,25 We found a comparable distribution of serum and intrahepatic HBsAg expression 
within the different HBV genotypes.
Finally, we showed in accordance with a previous study15 that expression of intrahepatic 
HBcAg differs between HBeAg positive and negative CHB. In the immune control phase, 
i.e after HBeAg seroconversion, intrahepatic HBcAg is usually undetectable.26 Loss of 
detectable HBcAg may also be associated with the emergence of precore stop-codon 
mutations during periods of cytotoxic T-cell clearance of virus-infected hepatocytes. 
The occurrence of these core gene mutations is associated with HBeAg negative chronic 
hepatitis B and active liver disease.27
A possible limitation of the current study is related to the fact that the follow-up biopsies 
were performed at different time points; in HBeAg positive CHB patients a second liver 
biopsy was performed directly post treatment (1 year), whereas in HBeAg negative CHB 
patients a second liver biopsy was performed at the end of 6 months of treatment free 
follow-up). Furthermore, sampling errors may have occurred during scoring of paired 
liver biopsies.
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In summary, we showed that PEG-IFN therapy reduces intrahepatic HBsAg expression. 
Loss of HBsAg from the liver predicts a sustained response, and is reflected in a pro-
nounced HBsAg decline in serum. Our results provide an important rationale for the use 
of HBsAg quantification as an easily obtainable estimate for prediction of response to 
PEG-IFN in both HBeAg positive and negative HBV patients.
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ABstrACt
Introduction
Several factors have been related to response to PEG-IFN in chronic hepatitis B (CHB). 
The occurrence of anti-IFN antibodies are associated with non-response to PEG-IFN in 
chronic hepatitis C. This study investigated the association between anti-IFN antibodies 
and response to PEG-IFN in CHB.
methods
Presence of anti-IFN antibodies was assessed at baseline and at 3 and 6 months post-
treatment in 323 CHB patients treated with PEG-IFN for one year.
results
At baseline anti-IFN antibodies were detected in 112 patients (35%). Prevalence was 
higher in HBeAg negative compared to HBeAg positive CHB (43% vs. 31%, respec-
tively, p=0.03). Detection of anti-IFN antibodies was not associated with age, sex or HBV 
genotype. Presence of anti-IFN antibodies at baseline was associated with previous IFN 
therapy failure (p=0.04), which remained after adjustment for HBeAg status (OR 2.0, 
95%CI 1.1-3.7, p=0.03). Presence of anti-IFN antibodies at baseline was not associated 
with response, nor with HBV DNA or HBsAg decline (all p-values>0.3). Fifty-six of 211 
(27%) patients without anti-IFN at baseline developed anti-IFN antibodies after PEG-IFN 
treatment. Response rates did not differ between patients who developed anti-IFN anti-
bodies and patients who did not develop anti-IFN antibodies during treatment (p=0.1).
Conclusion
Anti-IFN antibodies may frequently be detected in CHB patients, and presence is associ-
ated with previous IFN therapy. However, presence or development of anti-IFN antibod-
ies after PEG-IFN therapy is not associated with non-response to PEG-IFN treatment in 
CHB. There appears to be no future role for anti-IFN antibodies in predicting response 
to PEG-IFN in CHB.
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INtroDuCtIoN
Chronic hepatitis B (CHB) remains a major health problem, affecting over 350 million 
people worldwide. Many patients require treatment to prevent progression to cirrhosis, 
liver failure and hepatocellular carcinoma. Both nucleos(t)ide analogues and peginter-
feron (PEG-IFN) are registered for the treatment of CHB.1 Unlike nucleos(t)ide analogues, 
PEG-IFN does not only have antiviral, but also immunomodulating properties, which may 
play an important role in the elimination of the virus. Nevertheless, a finite treatment 
course with PEG-IFN results in a sustained response in only about 25% of patients.2,3
Recently, efforts have been made in determining the underlying pathophysiological 
mechanisms regarding response to PEG-IFN in CHB. Subsequently, several factors that 
are associated with a high probability of response have been identified which optimized 
the use of PEG-IFN in CHB. Currently known factors that may be used as baseline predic-
tors are HBV genotype, patient age, HBV DNA and ALT serum levels4, host IL28-B geno-
type5 and precore or basal core promoter mutants6 and serum IP-10 levels.7 However, 
the mechanism of (non)-response to PEG-IFN therapy is not well understood. The occur-
rence of anti-interferon (anti-IFN) antibodies has been reported after PEG-IFN therapy 
in chronic hepatitis C, and these antibodies may be associated with non-response to 
PEG-IFN based therapy.8,9 Anti-IFN antibodies may bind to interferon and interfere with 
its biological activity by blocking its interaction with its receptor.10 Previous Chinese 
studies showed that neutralizing anti-IFN antibodies may influence the effect of inter-
feron in CHB.11 However, the relation between the presence or development of anti-IFN 
antibodies and response to PEG-IFN is unknown. Therefore, the aim of this study was to 
investigate whether presence or development of anti-IFN antibodies is associated with 
non-response to PEG-IFN in HBeAg positive and negative CHB.
metHoDs
Patients
Presence of anti-IFN antibodies was assessed in CHB patients treated with PEG-IFN for 
one year. The first cohort consisted of HBeAg positive patients treated with PEG-IFN 
alfa-2b 100μg weekly in combination with placebo or lamivudine (LAM) 100 mg daily 
for 52 weeks. In- and exclusion criteria for this study have previously been described.2 
The second cohort comprised HBeAg negative patients who were treated with PEG-IFN 
alfa-2a 180μg weekly, either alone or in combination with ribavirin 1000mg (<75kg) or 
1200 mg (≥75kg) daily for 48 weeks. In- and exclusion criteria for this study have previ-
ously been described.3
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Inclusion criteria for the present analysis were completion of the 6 month follow-up 
phase of the main studies and available serum for detection of anti-IFN antibodies. 
Of the 404 patients in the initial studies, 323 fulfilled these criteria. Both studies were 
conducted in accordance with the guidelines of the Declaration of Helsinki and the prin-
ciples of Good Clinical Practice. All patients gave written informed consent according to 
standards of the local ethics committees.
Laboratory measurements
IFN binding antibodies (including neutralizing) were measured at baseline and at 3 and 
6 months post-treatment using a commercially available ELISA assay (Enzyme-linked 
immunosorbent assay for the quantitative detection of human anti-IFN-alpha, BMS217) 
in samples that were stored at -20 or -80° Celcius since the original studies. Serum HBV 
DNA and HBsAg were quantified in samples taken at baseline, during the treatment 
period and 6 months post-treatment. HBV DNA was measured using an in-house devel-
oped TaqMan polymerase chain reaction (PCR) assay (lower limit of quantification 400 
copies/mL). HBsAg was measured using the Abbott ARCHITECT HBsAg assay (Abbott 
laboratories; range 0.05 - 250 IU/mL).
statistical analysis
Since combination treatment with LAM2 or ribavirin3 did not influence response rates, 
data from the monotherapy and combination arms were pooled for the current analysis. 
Response was assessed at 6 months post treatment (week 78 in HBeAg positive patients, 
week 72 in HBeAg negative patients) and was defined as either HBeAg loss with HBV 
DNA <2000 IU/mL for HBeAg positive CHB or HBV DNA <2000 IU/mL with normal ALT for 
HBeAg negative patients. Associations between variables were tested using Student’s 
t-test, Chi-square, Pearson correlation or their non-parametric equivalents when ap-
propriate. SPSS version 15.0 (SPSS Inc., Chicago, IL, USA) was used to perform statistical 
analyses. All statistical tests were two-sided and were evaluated at the 0.05 level of 
significance.
role of the funding source
Financial support was provided by the Foundation for Liver and Gastrointestinal Re-
search (SLO) in Rotterdam, the Netherlands. The funding source did not have influence 
on study design, data collection, analysis and interpretation of the data, writing of the 
report nor the decision to submit for publication.
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resuLts
Baseline characteristics
The characteristics of the enrolled patients are shown in Table 1 by HBeAg status at 
baseline. Patients were predominantly male (76%), of Caucasian origin (80%) and har-
boured HBV genotype A in 28%, B in 6%, C in 11%, D in 52% and other genotypes in 
3%. At baseline, anti-IFN antibodies were detected (>1 ng/mL) in 112 patients (35%). 
Prevalence of anti-IFN antibodies was higher in HBeAg negative compared to HBeAg 
positive CHB (43% vs. 31%, respectively, p=0.03).
Detection of anti-IFN antibodies at baseline was not associated with age, sex or HBV 
genotype. However, anti-IFN antibodies were more often detected in patients treated 
with IFN in the past; 25 of 53 patients (47%) who were previously treated with IFN versus 
87 of 270 IFN-naïve patients (32%) had anti–IFN antibodies at baseline (p=0.04; Figure 
1A). After adjustment for HBeAg status, prior treatment with IFN remained associated 
with the presence of anti-IFN antibodies at baseline (OR 2.0, 95%CI 1.1-3.7, p=0.03).
Association with response to treatment
Sustained response was achieved in 43 (20%) of the HBeAg positive patients, and in 21 
(21%) of the HBeAg negative patients. There were no significant differences in response 
rates between patients with or without anti-IFN antibodies at baseline in either HBeAg 
positive, HBeAg negative or the overall population (all p-values >0.6; Figure 1B for the 
table 1. Baseline characteristics by HBeAg status at baseline
  overall HBeAg positive HBeAg negative 
p-value  N=323 N=221 N=102
Age (years) 36 ± 12 34 ± 12 41 ± 10 < 0.001
Male (%) 245 (76%) 173 (78%) 72 (71%) 0.133
Pretreatment with IFN (%) 53 (16%) 40 (18%) 13 (13%) 0.31
Genotype (%) < 0.001
A 89 (28%) 74 (33%) 15 (15%)
B 20 (6%) 20 (9%) 0 (0%)
C 34 (11%) 32 (15%) 2 (2%)
D 169 (52%) 87 (39%) 82 (80%)
Other 11 (3%) 8 (4%) 3 (3%)
ALT x ULN (U/l) 3.9 ± 2.9 4.3 ± 3.0 3.3 ± 2.7 0,004
Log HBV DNA (cop/mL) 8.4 ± 1.5 9.1 ± 0.9 6.8 ± 1.2 <0,001
Log qHBsAg 4.2 ± 0.7 4.4 ± 0.6 3.9 ± 0.5 <0,001
Presence of anti-IFN AB 112 (35%) 68 (31%) 44 (43%) 0,03
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overall population). Also when only IFN-naïve patients (N=270) were studied, presence 
of anti-IFN antibodies at baseline was not associated with response (23% vs. 21% in 
patients with or without anti-IFN antibodies at baseline respectively, p=0.8; Figure 1C). 
Presence of anti-IFN antibodies at baseline was not associated with HBV DNA decline 
(2.1 vs. 2.0, p=0.7) or HBsAg decline (0.8 vs. 0.8, p=0.8) during follow-up in the overall 
population. When HBeAg positive, HBeAg negative, IFN-naïve patients or patients within 
different treatment groups were studied separately no significant differences between 
the groups were found (all p-values >0.3).
Development of anti-interferon antibodies after Peg-IfN treatment
Of the 211 CHB patients without anti-IFN antibodies at baseline, 56 patients (27%) devel-
oped anti-IFN antibodies after PEG-IFN treatment. Although patients who did not develop 
anti-IFN antibodies showed higher response rates (22%) compared with patients who 
developed anti-IFN antibodies (11%), this was not significantly different (p=0.1; Figure 1D). 
Also when HBeAg positive and negative patients were studied separately, no significant 
differences were found. Furthermore, HBV DNA (2.2 vs. 1.8, p=0.2) and HBsAg decline (0.9 
vs. 0.5, p=0.1) during follow up did not significantly differ between both groups, both in 
the overall population, as well as in HBeAg positive and negative patients separately.
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figure 1. A) Presence of anti-IFN antibodies at baseline by previous interferon treatment
B) Response rates in the entire group by presence of anti-IFN antibodies at baseline.
C) Response rates in IFN-naïve patients by presence of anti-IFN antibodies at baseline.
D) Response rates in patients without anti-IFN antibodies at baseline.
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DIsCussIoN
This is the first study to describe the association of anti-IFN antibodies and response 
to PEG-IFN therapy in a large cohort of CHB patients. In our study, we found that a 
relatively large group of CHB patients had anti-IFN antibodies at baseline which was 
associated with previous IFN treatment. This is in accordance with previous studies in 
hepatitis C patients which showed the occurrence of anti-IFN antibodies after (PEG-)IFN 
therapy.9,12,13 Interestingly, in contradiction to a previous study in CHB patients treated 
with interferon, neutralizing anti-IFN antibodies were also found in treatment naïve 
patients.11 Natural antibodies to IFN-alfa have previously been reported in patients with 
cancer and various autoimmune disorders and there are data suggesting that elevated 
levels of antibodies to IFN are associated with stages of diseases related to disbalances 
of the immune system.14 Additionally, Ikeda et al found naturally occurring IgG anti-
IFN-alpha 2a in 50% and IgM anti-IFN-alpha 2a in 30% of patients with acute hepatitis 
B.15 These antibodies were detectable at the highest frequency three weeks after acute 
onset and subsequently became negative. However, the appearance of anti-IFN-alpha 
2a was not correlated with disease severity and there was no evidence to suggest that 
anti-IFN-alpha 2a impaired the elimination of the hepatitis virus.
Nevertheless, it is generally recognized that the development of antibodies against any 
auto-antigen or drug is unwanted. These antibodies may inhibit the pharmacological 
effects of drugs including exogenously administered interferons. However, in contrast 
to previous hepatitis C studies 8, we did not find an association between presence of 
anti-IFN antibodies at baseline and response to PEG-IFN in CHB. Furthermore, unlike a 
previous study in CHB patients treated with interferon11, development of anti-IFN anti-
bodies was not associated with non-response to PEG-IFN therapy. However, we should 
be cautious as the number of patients who developed anti-IFN antibodies in our study 
was relatively small and a larger group might have shown statistical significance.
Limitations of our study included the fact that we had a rather heterogeneous popula-
tion of HBeAg positive and negative patients who were treated with different regimens 
of PEG-IFN. We therefore performed all our analyses in different sub-groups.
Concluding, this study showed that anti-IFN antibodies may frequently be detected in 
CHB patients, and presence is associated with previous IFN therapy. However, presence 
or development of anti-IFN antibodies was not associated with non-response to PEG-
IFN treatment in CHB and there appears to be no future role for anti-IFN antibodies in 
predicting response to PEG-IFN in CHB.
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ABstrACt
Background & Aims
Serum levels of interferon-gamma inducible protein 10 (IP-10) are a marker for immune 
activity, and may predict response to peginterferon (PEG-IFN) therapy in chronic hepa-
titis B.
methods
IP-10 was measured at baseline and on-treatment week 12 in 210 HBeAg positive 
patients treated with PEG-IFN for 52 weeks. Response to treatment was assessed at 6 
months post-treatment and defined as HBeAg loss, combined response (HBeAg loss 
with HBV DNA<10,000c/mL) or HBsAg loss.
results
Median baseline IP-10 levels were 158.2 pg/mL. Higher baseline IP-10 was associ-
ated with more HBV DNA, HBeAg and HBsAg decline from week 4 onwards, and IP-10 
was higher in patients who achieved HBeAg loss (p=0.001) and combined response 
(p=0.052). A combination of high IP-10 (>150 pg/mL) with absence of precore (PC) 
and core promoter (BCP) mutants strongly predicted combined response and HBsAg 
loss: 48% of patients with high IP-10 and no detectable mutants achieved a combined 
response (p<0.001). IP-10 decline from baseline to week 12 was very limited, but more 
pronounced in patients who achieved HBeAg loss (0.05 log pg/mL, versus an increase of 
0.05 in patients without HBeAg loss, p=0.04).
Conclusions
Higher pre-treatment IP-10 levels are associated with an increased probability of HBeAg 
loss after PEG-IFN therapy. A combination of high baseline IP-10 and absence of PC and 
BCP mutants identified patients with the highest probability of combined response and 
HBsAg loss. There appears little use for on-treatment quantification of IP-10 for predic-
tion of response to PEG-IFN.
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INtroDuCtIoN
Peginterferon (PEG-IFN) is a first-line treatment option for chronic hepatitis B (CHB), 
because a finite treatment course may result in a sustained response in about 25% of 
patients.1-3 In HBeAg positive patients, HBV genotype, patient age, low baseline HBV 
DNA and high baseline ALT are independent predictors of response to PEG-IFN therapy.4 
Another recent study suggests that host IL28B genotype may also influence the prob-
ability of serological response to PEG-IFN,5 while absence of precore (PC) and basal core 
promoter (BCP) mutants may predict virologic response after HBeAg clearance.6 The as-
sociation of both high ALT and IL28B genotype with response to PEG-IFN suggests that 
successful induction of an immune response with PEG-IFN depends upon a susceptible 
host in combination with an active immune response, and biomarkers of immune activ-
ity may therefore predict response to treatment.
The interferon-gamma inducible protein 10 (IP-10), also known as chemokine C-X-C 
motif ligand (CXCL-)10, targets the CXC3 receptor, attracts T-lymphocytes and influences 
T-cell as well as natural killer cell adhesion.7-9 Therefore, serum levels of IP-10 may be 
a marker for immune activity.10 Pre-treatment IP-10 levels appear to predict response 
to PEG-IFN therapy in chronic hepatitis C patients,10-13 independent of other known 
predictors, such as viral load, HCV genotype and stage of liver disease.10,12,13 Moreover, 
recent studies have shown that quantification of IP-10 may add substantially to IL28B 
genotyping when aiming to predict a sustained response in hepatitis C patients, pos-
sibly through an association with interferon stimulated gene expression.14-16
Although the precise role of IP-10 in CHB remains unclear, one previous study showed 
that IP-10 kinetics are associated with the occurrence of flares in CHB patients. These 
findings suggest that serum levels of IP-10 could reflect the immune activity of patients, 
and consequently predict response to PEG-IFN therapy.17
The aim of the current study was therefore to investigate the relationship between 
serum levels of IP-10 and response to PEG-IFN in HBeAg positive CHB patients.
PAtIeNts AND metHoDs
Patients
In this study, serum levels of IP-10 were measured before treatment initiation and at 
week 12 of treatment in 210 HBeAg positive CHB patients treated with PEG-IFN alfa-
2b within an investigator-initiated multicenter randomized trial.1,18,19 The inclusion and 
exclusion criteria for this study have previously been described elsewhere.1 In summary, 
patients were eligible if they had been HBsAg positive for at least 6 months before 
randomization, were HBeAg positive, had elevated serum alanine aminotransferase 
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(ALT) levels of >2, but <10 times the upper limit of normal (ULN), and had a serum HBV 
DNA concentration of more than 100,000 copies/mL. Patients were treated with PEG-IFN 
alfa-2b 100 μg weekly (PegIntron, Schering-Plough, Kenilworth, NJ, USA) in combination 
with placebo or lamivudine (LAM) 100 mg (Zeffix, GlaxoSmithKline, Greenford, UK) daily 
for 52 weeks. Inclusion criteria for the present analysis were completion of the 26-week 
post-treatment follow-up phase of the main study, data on PC / BCP mutants at baseline, 
and available serum for IP-10 assessment at baseline. Of the 266 patients in the initial 
study, 210 fulfilled these criteria.
The study was conducted in accordance with the guidelines of the Declaration of 
Helsinki and the principles of Good Clinical Practice. All patients gave written informed 
consent according to standards of the local ethics committees.
Laboratory measurements
Serum IP-10 was assessed at baseline and at week 12 of treatment using a commercially 
available ELISA kit (Alta Analytical Laboratory, San Diego, USA) in samples that were 
stored at -80° Celcius since the original studies . The presence of PC and BCP mutants 
was assessed using the INNO-LiPA HBV PreCore assay (Innogenetics, Ghent, Belgium). 
This very sensitive line probe assay allows for easy detection of PC (at nucleotide posi-
tion G1896) and BCP (at nucleotide positions A1762 and G1764) mutants.20 Patients were 
classified as wildtype (WT, only WT virus detectable), or as non-WT (when either PC, BCP 
or both mutants were detected). Serum HBV DNA, HBeAg and HBsAg were quantified in 
samples taken at baseline, during the treatment period and at 6 months post-treatment. 
HBV DNA was measured using an in-house developed TaqMan polymerase chain reac-
tion (PCR) assay (lower limit of quantification 400 copies/mL).21 HBsAg was measured 
using the Abbott ARCHITECT HBsAg assay (Abbott laboratories; range 0.05 - 250 IU/mL) 
and HBeAg with the Roche ELECSYS HBeAg assay using a quantitative protocol (Roche 
Diagnostics, range 0.2 – 100 IU/ml).
statistical analysis
Response was assessed at 6 months post-treatment (week 78) and was defined as either 
HBeAg loss, HBeAg loss with HBV DNA <10,000 copies/mL (combined response) or HB-
sAg loss. Associations between variables were tested using Student’s t-test, Chi-square, 
Pearson correlation or their non-parametric equivalents when appropriate. SPSS version 
15.0 (SPSS Inc., Chicago, IL, USA) and the SAS 9.2 program (SAS Institute Inc., Cary, NC, 
USA) were used to perform statistical analyses. All statistical tests were two-sided and 
were evaluated at the 0.05 level of significance.
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role of the funding source
Financial support was provided by the Foundation for Liver and Gastrointestinal Re-
search (SLO) in Rotterdam, the Netherlands. The funding source did not have influence 
on study design, data collection, analysis and interpretation of the data, writing of the 
report nor the decision to submit for publication.
resuLts
Patient characteristics
The characteristics of the enrolled patients are shown in table 1. Overall, 75 (36%) 
cleared HBeAg, 39 (19%) achieved a combined response and 17 (8%) cleared HBsAg. 
Since combination treatment with lamivudine did not influence response rates1, data 
from the monotherapy and combination arms were pooled for the current analysis. 
Treatment allocation was controlled for in multivariate analyses whenever applicable. 
Median baseline level of IP-10 was 158.2 pg/mL (range: 6.6 – 1500 pg/mL). IP-10 levels 
were logarithmically transformed for further analysis, and also divided into quartiles: 
quartile 1 (<2.02 log pg/mL), quartile 2 (2.02 – 2.20 log pg/mL), quartile 3 (2.20 – 2.42 log 
pg/mL) and quartile 4 (>2.42 log pg/mL).
relationship between IP-10 levels and baseline characteristics
Baseline IP-10 levels did not significantly differ across the HBV genotypes A through D, 
across patients with different ethnicities, nor among patients with only WT virus versus 
those with detectable PC and/or BCP mutants. Baseline IP-10 level did not correlate with 
baseline HBV DNA, HBeAg, or HBsAg levels, but was significantly associated with patient 
age (r=0.23, p=0.001) and correlated strongly with baseline ALT (r=0.45, p<0.001).
Association of baseline IP-10 with on-treatment decline of HBv DNA, HBeAg 
and HBsAg
Higher baseline IP-10 level was associated with more HBV DNA (p=0.001), HBeAg 
(p<0.001) and HBsAg decline (p=0.028) at 6 months after PEG-IFN discontinuation (week 
78). Figure 1A-C shows the on-treatment declines in HBV DNA, HBeAg and HBsAg strati-
fied by a baseline IP-10 level of 150 pg/mL (~median). Importantly, a baseline IP-10 level 
>150 pg/mL independently predicted HBsAg decline at week 78 when adjusted for HBV 
genotype, presence of only WT virus and baseline HBsAg. Adjusted HBsAg decline for 
patients with an IP-10 >150 pg/mL was 1.38 log IU/mL, compared to 0.89 for those with 
an IP-10 <150 pg/mL (p=0.034). In similar models, baseline IP-10 level > 150 pg/mL was 
associated with more HBeAg decline (1.35 vs. 0.83 log IU/mL, p=0.002) and HBV DNA 
decline (3.00 vs. 1.96 log c/mL, p=0.002). Combination therapy did not predict HBsAg, 
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HBeAg or HBV DNA decline at week 78 in these models (p≥0.370). Importantly, the 
association between high IP-10 level at baseline (>150 pg/mL) and more pronounced 
on-treatment decline was apparent as soon as week 4 of treatment for HBsAg (p<0.001), 
HBeAg (p=0.002) and HBV DNA (p<0.001), when adjusting for HBV genotype, presence 
of only WT virus, baseline level and combination therapy.
Baseline IP-10 levels and response at 6 months post-treatment
Baseline IP-10 level was higher in patients who cleared HBeAg by week 78 when com-
pared to those who did not (2.34 vs. 2.17 pg/mL, p=0.001), as was the case for patients 
who achieved a combined response versus those who did not (2.32 vs. 2.21 log pg/
mL, p=0.052). The association between baseline IP-10 level (in quartiles) and probability 
table 1. Characteristics of the study cohort
Characteristics
Demography
 Mean (SD) age, years 33.7 (12)
 Male 164 (78%)
Previous IfN therapy 38 (18%)
Peg-IfN monotherapy 102 (49%)
race
 Caucasian 153 (73%)
 Asian 40 (19%)
 Other 17 (8%)
Laboratory results
 Mean (SD) ALT* 4.3 (3.0)
 Mean (SD) HBV DNA, log c/mL 9.1 (0.89)
 Mean (SD) HBsAg, log IU/mL 4.4 (0.60)
 Mean (SD) HBeAg, log IU/mL 2.5 (0.70)
 Median (range) IP-10, pg/mL 158.2 (6.6-1500)
HBv genotype
 A 73 (35%)
 B 19 (9%)
 C 29 (14%)
 D 82 (39%)
 Other/mixed 7 (3%)
INNo-LiPA result
 Wildtype 76 (36%)
 Precore 54 (26%)
 Basal core promoter 45 (21%)
 Precore and basal core 35 (17%)
*Multiples of upper limit of the normal range
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figure 1. Relationship between baseline IP-10 level and on-treatment viral decline. Decline of serum HBV 
DNA (A), HBeAg (B) and HBsAg (C) during treatment by baseline IP-10 level (n=210).
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of response at 6 months post-treatment is shown in figure 2. In multivariate analysis, 
IP-10 levels at baseline were significantly associated with the occurrence of HBeAg clear-
ance (adjusted OR: 3.60, 95% CI: 1.15 – 11.22, p=0.024, table 2) when adjusting for HBV 
genotype, presence of only WT virus, baseline age, HBV DNA and ALT and previous IFN 
treatment failure. Of note, presence of PC and/or BCP mutants was not an independent 
predictor of HBeAg loss after PEG-IFN therapy, nor was combination therapy. Interest-
ingly, serum IP-10 at baseline was not significantly associated with the occurrence of a 
combined response (adjusted OR: 2.48, 95% CI: 0.59 – 10.48, p=0.21, table 2).
A combination of IP-10 and presence of only Wt virus identifies patients with a 
high likelihood of response
Since baseline levels of IP-10 was associated with HBeAg loss, but not combined re-
sponse, whereas presence of only WT virus was previously shown to be associated with 
achievement of low HBV DNA levels after HBeAg clearance6, we explored the interplay 
between these two variables. In a model for combined response, an interaction term 
between WT virus and baseline IP-10 level was highly significant (p=0.002), indicating 
that the association of IP-10 levels with response is not the same for patients with WT 
virus compared to those with detectable mutants at baseline. A similar interaction was 
also found for WT virus and baseline ALT (p=0.030). Such an interaction was not found 
when HBeAg loss was considered (p=0.15 for interaction of IP-10 and WT, p=1.0 for ALT 
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figure 2. Baseline IP-10 and response at 6 months post-treatment.
Relationship between baseline IP-10 and response to treatment in the HBeAg-positive population in the 
overall cohort
Interferon gamma-inducible protein-10 level and response to peginterferon 53
table 2. Logistic regression model of probability of response to peginterferon in HBeAg positive patients
HBeAg loss week 78 Combined response week 78
variable or (95% CI) p variable or (95% CI) p
IP-10* 3.60 (1.15 – 11.2) 0.024 IP-10* 2.48 (0.59 – 10.5) 0.209
Wildtype 1.11 (0.50 – 2.46) 0.799 Wildtype 3.45 (1.30 – 9.18) 0.011
HBV Genotype 0.001 HBV Genotype 0.048
 A Reference  A Reference
 B 0.62 (0.18 – 2.13)  B 0.52 (0.12 – 2.19)
 C 0.10 (0.03 – 0.37)  C 0.11 (0.02 – 0.61)
 D 0.45 (0.18 – 1.14)  D 0.33 (0.10 – 1.12)
ALT# 1.11 (0.99 – 1.25) 0.081 ALT# 1.06 (0.90 – 1.25) 0.528
Age 1.02 (0.99 – 1.05) 0.280 Age 1.04 (1.00 – 1.07) 0.036
HBV DNA** 0.58 (0.38 – 0.88) 0.010 HBV DNA** 0.55 (0.32 – 0.94) 0.031
No previous IFN 3.74 (1.50 – 9.32) 0.003 No previous IFN 5.07 (1.49 – 17.3) 0.004
Combined response was defined as HBeAg loss with HBV DNA <10,000 c/mL at 6 months post-treatment. 
*IP-10 in log pg/mL, **HBV DNA in log copies/mL, #ALT in x ULN.
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figure 3. Predicted probability for response as a function of baseline IP-10.
Estimated probability of combined response (HBeAg loss and HBV DNA <10,000 c/mL) stratified by pres-
ence of precore and/or core promoter mutants
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and WT). Figure 3 shows the estimated probability of combined response as predicted 
by the prediction model shown in table 2, with addition of an interaction term of WT 
with IP-10. The probability of response for patients with only WT virus strongly improved 
with increasing IP-10 level, and similar findings were obtained with ALT. In contrast, pa-
tients with detectable PC and/or BCP mutants did not benefit from higher IP-10 or ALT 
levels. A combination of baseline IP-10 >150 pg/mL and absence of PC and BCP mutants 
could identify patients with a very high likelihood of response (figure 4). Furthermore, it 
can also be inferred from figure 4 that high IP-10 level at baseline predisposes to HBeAg 
clearance after PEG-IFN therapy, but that this did not translate to increased combined 
response rates or HBsAg loss if PC and/or BCP mutants were present.
on-treatment IP-10 and response to treatment
IP-10 levels remained stable from baseline to week 12; a minimal non-significant decline 
was observed of 0.015 log pg/mL (p=0.52 compared to baseline). IP-10 decline was more 
pronounced in patients who achieved HBeAg loss (0.05 log pg/mL decline, versus an 
increase of 0.05 in patients without HBeAg loss, p=0.04), and the proportion of patients 
who achieved a decline of IP-10 from baseline was higher among patients with HBeAg 
loss (59 versus 42%, p=0.024) and combined responders (60 versus 45%, p=0.11). Pa-
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figure 4. Observed response rates by baseline IP-10 and presence of PC and BCP mutants.
The probability of combined response according to a baseline IP-10 in combination with presence or ab-
sence of precore and/or core promoter mutants.
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tients with an IP-10 decrease at week 12 achieved more HBV DNA decline (2.55 versus 
1.85 log c/mL, p=0.06), HBeAg decline (1.24 versus 0.84 log IU/mL, p=0.029) but not 
HBsAg decline (1.04 versus 0.75, p=0.26).
DIsCussIoN
This is the first study to describe the association of IP-10 level and response to PEG-IFN 
therapy in CHB. In our study, higher baseline level of IP-10 strongly predicted HBeAg 
loss after PEG-IFN therapy, and a combination of high IP-10 and presence of only WT 
virus identified patients with a high likelihood of combined serological and virologic 
response.
PEG-IFN is a valuable treatment option for CHB, for it is the only agent that can be ex-
pected to induce a sustained off-treatment response after a finite treatment course.22 
However, the limited response rates observed in the general CHB patient population 
necessitate careful selection of patients.23 Our group recently published a baseline pre-
diction model that can help clinicians identify HBeAg positive patients with a high likeli-
hood of response4, and extensions with host and viral factors have been proposed.5,6,24 
The current study shows that response to PEG-IFN in HBeAg positive patients also 
depends upon pre-treatment serum level of IP-10. Importantly, the association of IP-10 
with response to treatment is already apparent from week 4 of therapy, as shown by the 
more pronounced HBV DNA, HBeAg and HBsAg decline observed in patients with higher 
levels of IP-10 at baseline. Given the strong association of IP-10 with ALT, high levels 
of IP-10 may be a proxy for an active host immune response, resulting in more active 
liver inflammation.25 Importantly, blocking the effects of IP-10 may reduce liver damage 
in mice,26 further supporting the association of IP-10 with immune activity. These find-
ings are corroborated by recent data from Cornberg et al, showing more pronounced 
HBsAg decline in nucleo(s)tide analogue treated patients with high IP-10 levels.27 The 
association with immune activity is further strengthened by the observation that IP-10 
levels decline during PEG-IFN therapy in patients who achieve a response, mimicking 
reductions in intrahepatic inflammation previously observed in responders to PEG-IFN.1 
Previous studies have shown that a pre-existing immune response may be a pre-requi-
site for response to PEG-IFN therapy,4,28 and the current study shows that serum levels 
of IP-10 may help identify patients with such favourable characteristics. Nevertheless, 
the observed IP-10 decline in responders is very limited, restraining the use of IP-10 
as an on-treatment predictor of response to PEG-IFN therapy in HBeAg positive CHB. 
Furthermore, recent studies in HCV infected patients treated with PEG-IFN have shown 
that a slight increase in IP-10 levels may be observed after PEG-IFN dosing, which may 
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also reduce the reliability of IP-10 quantification during treatment. The current study 
therefore does not support the use of IP-10 for on-treatment decision-making in HBeAg 
positive CHB patients treated with PEG-IFN.12
It should be appreciated that baseline and on-treatment IP-10 levels appear to be 
mainly associated with the probability of HBeAg clearance after PEG-IFN therapy, and 
less so with a combined serological and virologic response. Persistence of viral replica-
tion after HBeAg loss may be accounted for by the presence PC and BCP mutants, which 
can be detected in a considerable proportion of HBeAg positive patients.6 Combining 
levels of IP-10 and presence of PC and BCP mutants showed that both contribute to 
the achievement of a combined serological and virologic response; patients with both 
a high baseline level of IP-10 and absent mutants achieved high rates of combined re-
sponse, whereas patients with a high IP-10 level with detectable mutants progressed to 
active HBeAg negative CHB. A similar association was found if a combination of baseline 
ALT and presence of mutants was explored, further illustrating the importance of ac-
tive inflammation. Based on these findings, we propose that combined serological and 
virologic response to PEG-IFN in HBeAg positive CHB requires both a susceptible host 
(high IP-10, high ALT), as well as a susceptible virus (absence of PC and BCP mutants).
Concluding, high levels of IP-10 predict HBeAg loss, and a combination of high IP-10 and 
absent PC and BCP mutants predicts combined serological and virologic response to 
PEG-IFN in HBeAg positive CHB. There appears little use for on-treatment quantification 
of IP-10 for prediction of response to PEG-IFN in CHB.
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ABstrACt
Background
Hepatocellular carcinoma (HCC) risk-scores may predict HCC in Asian entecavir (ETV) 
treated patients. We aimed to study risk factors and performance of risk scores during 
ETV treatment in an ethnically diverse Western population.
methods
We studied all HBV mono-infected patients treated with ETV from 11 European referral 
centers within the VIRGIL Network.
results
A total of 744 patients were included; 42% Caucasian, 29% Asian, 19% other, 10% 
unknown. At baseline, 164 patients (22%) had cirrhosis. During a median follow-up of 
167 (IQR 82-212) weeks, 14 patients developed HCC of whom nine (64%) had cirrhosis 
at baseline. The 5-year cumulative incidence rate of HCC was 2.1% for non-cirrhotic 
and 10.9% for cirrhotic patients (p<0.001). HCC incidence was higher in older patients 
(p<0.001) and patients with lower baseline platelet counts (p=0.02). Twelve patients 
who developed HCC achieved virologic response (HBV DNA<80IU/mL) before HCC. At 
baseline, higher CU-HCC and GAG-HCC, but not REACH-B scores were associated with 
development of HCC. Discriminatory performance of HCC risk scores was low with sen-
sitivity ranging from 18-73% and c-statistics from 0.71 to 0.85. Performance was further 
reduced in Caucasians with c-statistics from 0.54 to 0.74. Predicted risk of HCC based on 
risk-scores declined during ETV therapy (all p<0.001), but predictive performances after 
one year were comparable to those at baseline.
Conclusion
Cumulative incidence of HCC is low in patients treated with ETV, but ETV does not 
eliminate the risk of HCC. Discriminatory performance of HCC risk-scores was limited, 
particularly in Caucasians, both at baseline and during therapy.
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INtroDuCtIoN
The goal of treatment of chronic hepatitis B (CHB) infection is to prevent disease pro-
gression to (decompensated) cirrhosis, hepatocellular carcinoma (HCC) and death.1 
Current treatment guidelines consider nucleos(t)ide analogues (NA) or peginterferon 
(PEG-IFN) as first line treatment for CHB in patients with serum HBV DNA level >2.000 IU/
mL in combination with elevated ALT levels (>1-2x ULN) or with moderate to severe liver 
inflammation and/or fibrosis.2,3 These guidelines are based on the accepted association 
between HBV DNA levels and progression to cirrhosis, HCC and liver-related mortality 
in untreated patients.4 Entecavir (ETV) inhibits HBV replication in the vast majority of 
patients and is also able to improve fibrosis scores after continuous therapy in 88% of 
CHB patients.5 Furthermore, ETV therapy may reduce the risk of HCC and liver related 
events, particularly in patients with cirrhosis.6-8 Nevertheless, the residual risk of HCC 
necessitates intensive on-going follow-up of patients with successfully suppressed viral 
replication.2 Recently, risk scores based on demographic (age and sex), clinical (cirrhosis, 
ALT, albumin and bilirubin) and virologic (HBeAg status, HBV DNA) characteristics have 
been developed in order to predict the risk of HCC in treatment-naïve patients. These 
HCC risk scores were shown to predict HCC in Asian CHB patients treated with ETV as 
well.9 However, the performance of these risk-scores in non-Asian patients remains un-
clear. The aims of the current study were therefore to investigate in this large ethnically 
diverse European HBV infected population treated with ETV 1) the incidence of, and 
risk factors for, development of liver related events including HCC and 2) the role of 
risk-scores for prediction of HCC.
mAterIALs AND metHoDs
study population
In this investigator-initiated cohort study within the European network of excellence for 
Vigilance against Viral Resistance (VIRGIL), all consecutive CHB patients (HBsAg positive 
for at least 6 months) treated with ETV monotherapy for at least 3 months between 
2005 and May 2013 in 11 large European referral centers were included. Patients were 
excluded if they were co-infected with HIV, HCV or HDV or if they had an HCC at baseline. 
Patients’ ethnicity was classified as Caucasian, Asian (including only East-Asians from e.g. 
China, Hong Kong and Thailand) or other (including sub-Saharan Africans). A total of 744 
patients were eligible for the current analysis. The study was conducted in accordance 
with the guidelines of the Declaration of Helsinki and the principles of Good Clinical 
Practice. Patients gave written informed consent according to standards of the local 
ethics committees.
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follow-up of participants
All subjects were prospectively monitored every three to six months at the discretion of 
the local treating physician. At every visit routine examination with biochemical (serum 
ALT, bilirubin, albumin, INR and creatinine) and virologic (HBsAg, HBeAg, anti-HBe, HBV 
DNA level) assessments took place. The diagnosis of cirrhosis at baseline was based on 
histology or ultrasound examinations with signs of cirrhosis (spleen size >12 cm, portal 
vein>16 mm, or nodules within the hepatic parenchyma).6 In cirrhotic patients screening 
for HCC was performed at least yearly by ultrasound and/or alpha-fetoprotein measure-
ment. In non-cirrhotic patients HCC surveillance varied from centre to centre according 
to local protocols and was only performed when other risk factors were present.3
endpoints
HCC was defined by either i) histological confirmation, or ii) two parallel imaging tech-
niques (ultrasound, computerised tomography, or magnetic resonance imaging) show-
ing a focal lesion larger than 2 cm with arterial hypervascularization, or iii) one imaging 
technique showing a focal lesion larger than 2 cm with arterial hypervascularization in 
the presence of an alpha fetoprotein level greater than 400 ng/mL.
Clinical events were defined as a composite endpoint of development of HCC, liver de-
compensation, or death during the study period. Diagnosis of decompensated cirrhosis 
was based on the presence of ascites confirmed by ultrasound, jaundice with a serum 
bilirubin level >2.0 mg/dL, bleeding esophageal varices, or hepatic encephalopathy in 
cirrhotic patients. Other reported endpoints were virologic response (VR, HBV DNA level 
< 80 IU/mL), HBeAg loss (in HBeAg-positive patients) and HBsAg loss all during the on-
treatment follow-up period.
Laboratory tests
Serum alanine aminotransferase (ALT), bilirubin, albumin levels and international 
ratio of prothrombin time (INR) were measured locally using standardized automated 
techniques. Hepatitis B surface antigen (HBsAg), antibody against HBsAg (anti-HBs), 
hepatitis B e antigen (HBeAg), and antibody against HBeAg (anti-HBe) were determined 
using commercially available enzyme immunoassays in all centers. Serum HBV DNA 
levels were measured using a quantitative real-time polymerase chain reaction assay, 
the COBAS AmpliPrep-COBAS TaqMan HBV test (CAP-CTM; Roche Molecular Systems, 
Inc., Branchburg, NJ, USA), with a lower limit of detection of 12 IU/mL, in ten of eleven 
centers. In one center serum HBV DNA was measured using Roche Amplicor (linear 
dynamic range, 400 to 200,000 copies/mL; Roche Diagnostic Systems, Branchburg, NJ, 
USA). A conversion factor of 5.26 copies/IU was used for conversion of copies/mL to IU/
mL. HBV genotypes and detection of HBV polymerase gene mutations was determined 
by direct sequencing or using the INNO-LiPA assay (Innogenetics, Gent, Belgium).
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Data analysis
Data acquisition directly from the patients’ charts was performed on site by a single 
experienced investigator (PA). Data were systematically collected through a standard-
ized clinical record form. HBV DNA levels were logarithmically transformed for analysis. 
ALT levels are expressed as values representing a ratio to the local upper limit of normal 
(xULN). Continuous variables are expressed as means ± SD or median (IQR) where ap-
propriate. Follow-up times were calculated from the date of ETV treatment initiation to 
the date of event or end of follow-up. Components of the HCC risk scores included age, 
cirrhosis, albumin, bilirubin and HBV DNA level for the CU-HCC risk score10; age, cirrhosis, 
sex and HBV DNA for the GAG-HCC risk score11; and age, sex, ALT, HBeAg status and HBV 
DNA for the REACH-B risk score12. The cumulative probability of achieving primary or 
secondary endpoints was estimated by Kaplan-Meier analysis. Cox’s regression analysis 
was used to study which baseline factors were associated with primary or secondary 
endpoints. The influence of VR was analyzed as a time-dependent covariate allowing 
patients to be at risk in either the VR or non-VR group according to HBV DNA level during 
follow-up. Therefore VR was entered in the model as a time-dependent covariate: all 
patients started (and thus at risk) within the group without VR and were switched to 
the group with VR after achieving this endpoint. Sensitivity, negative predictive values 
(NPVs), and c-statistics of the risk scores to predict HCC were estimated and reported, 
both within the entire population as well as in a subgroup of Caucasian patients.
All statistical tests were two-sided, and a P value < 0.05 was considered to be statistically 
significant. SPSS version 20.0 (SPSS Inc., Chicago, IL, USA) and SAS 9.2 program (SAS 
Institute Inc., Cary, NC, USA) were used for all statistical analyses.
resuLts
Baseline characteristics
In total, 891 chronic HBV patients treated with ETV were identified. One hundred and 
forty-seven patients did not fulfill the entry criteria and were excluded; 70 patients were 
treated for less than 3 months, 19 patients were co-infected with HCV or HDV, 22 patients 
had an HCC at baseline, two patients had undergone liver transplantation, two patients 
were HBsAg negative at baseline, 30 patients received concomitant antiviral therapy 
and two were non-compliant. A total of 744 CHB patients treated with ETV monotherapy 
were thus eligible and included. Baseline characteristics of the study population are 
shown in table 1 according to the presence of cirrhosis. Forty-two percent of patients 
were of Caucasian origin, 29% Asian, 19% other and in 10% ethnicity was unknown. 
At baseline 164 patients (22%) had cirrhosis (by ultrasound or histology), 239 patients 
(32%) were HBeAg positive, median ALT was 1.4 x ULN (IQR 0.8 – 2.7) and mean HBV 
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DNA 5.3 log IU/mL (6.6 log IU/mL for HBeAg positive and 4.5 log IU/mL for HBeAg nega-
tive patients). Overall median follow-up was 167 weeks (IQR 82-212) and did not differ 
between cirrhotic and non-cirrhotic patients (p=0.22). Total number of visits was 7160 
with a median number of visits per patient of 8 (IQR 5-11), with a median interval of 14 
(IQR 12-25)
table 1. Baseline characteristics
All (n=744) cirrhosis (n=164)
no cirrhosis 
(n=580) p
Male (%) 569 (77%) 138 (84%) 431 (74%) 0.009
Mean age 44 ± 14 51 ± 13 42 ± 13 <0.001
ETV dosage 0.5mg (%) 640 (86%) 123 (75%) 517 (89%) <0.001
Race 0.37
Caucasian 316 (42%) 74 (45%) 242 (42%)
Asian 214 (29%) 41 (25%) 173 (30%)
Other 139 (19%) 26 (16%) 113 (19%)
Unknown 75 (10%) 23 (14%) 52 (9%)
Genotype 0.64
A 100 (13%) 23 (14%) 77 (13%)
B 48 (7%) 7 (4%) 41 (8%)
C 78 (11%) 17 (10%) 61 (11%)
D 186 (25%) 40 (24%) 146 (25%)
E 52 (7%) 8 (5%) 44 (8%)
Other 5 (1%) 1 (1%) 4 (1%)
Unknown 275 (37%) 68 (41%) 207 (36%)
HBeAg positive 239 (32%) 54 (33%) 185 (32%) 0.92
Mean HBV DNA (log IU/mL) 5.3 ± 2.2 5.4 ± 2.2 5.2 ± 2.2 0.29
Median ALT (xULN) 1.4 (0.8-2.7) 1,5 (1-3,2) 1,4 (0,8-2,5) 0.57
Platelet count (x10E9/L)* 192 ± 72 138 ± 63 210 ± 66 <0.001
Median bilirubin (umol/L) 11 (8-15) 14 (10-20) 10 (7-14) 0.001
Albumin (g/dL)** 4.3 ± 0.5 4.1 ± 0.6 4.4 ± 0.4 <0.001
PT INR+ 1.1 ± 0.2 1.2 ± 0.2 1.1 ± 0.2 <0.001
Mean CU HCC risk score++ 8 ± 9 23 ± 9 4 ± 4 <0.001
Mean GAG HCC risk score 62 ± 18 82 ± 14 56 ± 14 <0.001
Mean REACH-B score 9 ± 3 11 ± 3 9 ± 3 <0.001
NA-naive 569 (77%) 108 (66%) 461 (80%) <0.001
LAM-naive 617 (83%) 122 (74%) 495 (85%) 0.001
IFN-naive 610 (82%) 138 (84%) 472 (81%) 0.49
Data are represented as mean (± standard deviation) or median (IQR).
Data available for *73%, **75%, +63% and ++69% of patients, respectively
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virologic response during treatment
HBV DNA < 80 IU/mL (virologic response, VR) was achieved in 655 patients. The cumula-
tive probability of VR was 53%, 76%, 90%, 94%, 97% and 99% at six months and years 
1, 2, 3, 4 and 5, respectively. VR was not influenced by the presence of cirrhosis (p>0.2). 
HBeAg loss was achieved in 85 (36%) of 239 HBeAg positive patients. The cumulative 
probability of HBeAg loss was 11%, 25%, 36%, 45% and 58% at years 1, 2, 3, 4 and 5 and 
was higher in patients with cirrhosis (p=0.03). Sixteen patients (2.2%) achieved HBsAg 
loss. The cumulative probability of HBsAg loss was 0.1%, 1.2%, 1.6%, 2.3% and 4.1% at 
years 1, 2, 3, 4 and 5.
Development of HCC
Fourteen patients developed HCC (7 Caucasians), after a median duration of 125 weeks 
(IQR 59-188). The cumulative probability of developing HCC was 2.1% for non-cirrhotic 
versus 10.9% for cirrhotic patients at year five of follow-up (p<0.001) (Figure 1). Risk of 
HCC was higher in patients with cirrhosis (p=0.002), older patients (>50 years) (p<0.001), 
in patients with lower platelet counts (p=0.02), and in patients who were previously 
treated with lamivudine (p=0.03). When Caucasian patients were studied separately, 
only age was associated with the occurrence of HCC (HR 1.06, 95% CI 1-1.13, p=0.05). 
(Table 2)
0 2 4 6
0
10
20
30
40
No cirrhosis
Cirrhosis
P<0.001
No. at risk
Cirrhosis
No cirrhosis
164           145           112           96             54              28             7
580           502           404          315           147             56           11
Follow-up (years)
Cu
m
ul
at
iv
e 
pr
ob
ab
ili
ty
 o
f H
CC
 (%
)
Ch 4 fig 1.pzf:Data 2 - Tue Jul 15 13:29:18 2014
figure 1. Kaplan-Meier curve for the cumulative probability of developing HCC according to presence of 
cirrhosis
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occurrence of clinical events
Overall, 34 patients developed a clinical event (including 14 HCC) after a median du-
ration of 87 weeks (IQR 49-169). Twenty-three (68%) had cirrhosis at baseline. Of the 
14 patients who developed HCC, three patients died. Thirteen patients developed an 
episode of hepatic decompensation of whom five patients died. Overall, 17 patients 
died during follow-up, eight liver related and nine of other causes. (Table 3)
Influence of virologic response and development of HCC and clinical events
In patients without a clinical event median time to VR was 23 weeks (IQR 12-47). Of 14 
patients who developed HCC, 12 patients already achieved VR before HCC was diag-
nosed. The other 2 patients achieved response after the occurrence of HCC. Median time 
to VR was 24 weeks (IQR 13-41) in patients with HCC. Of the 34 patients with a clinical 
event, 30 patients achieved VR. Median time to VR in patients who developed a clinical 
events was 27 weeks (IQR 17-56). In a Cox regression analysis with VR as time-dependent 
factor HBV DNA < 80 IU/mL was neither significantly associated with the development 
of HCC (HR 0.87, 95%CI 0.17-4.58, p=0.87), nor with the development of a clinical event 
(HR 0.70, 95%CI 0.28-1.77, p=0.46).
Performance of HCC risk scores at baseline
At baseline, mean risk-score was 8 for CU-HCC, 62 for GAG-HCC and 9 for REACH-B. 
Higher CU-HCC and GAG-HCC, but not REACH-B scores were associated with HCC in the 
overall population.
When established cut-off values for these risk scores were used (5 for the CU-HCC score, 
101 for the GAG-HCC score and 8 for the REACH-B score), only CU-HCC and GAG-HCC 
risk scores were predictive for HCC development (table 4). C-statistics for the overall 
population were 0.78 for CU-HCC, 0.85 for GAG-HCC and 0.71 for REACH-B risk score. 
In Caucasians the scores were 0.66, 0.74 and 0.54, for CU-HCC, GAG-HCC and REACH-B, 
respectively. Negative predictive values (NPVs) at 4 years of therapy for all risk scores at 
baseline were more than 95% (CU-HCC 84/86, GAG-HCC 184/193 and REACH-B 39/41) 
with a sensitivity ranging from 18% (2/11) for GAG-HCC, 78% (7/9) for CU-HCC and 82% 
table 3. Distribution of clinical events
Cirrhosis (n=164) No cirrhosis (n=580)
Decompensation (n) HCC (n) Death (n) HCC (n) Death (n)
Overall 11 9 3 5 6
Caucasian 6 4 2 3 5
Asian 1 2 0 2 0
Other 4 3 1 0 1
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(9/11) for REACH-B. Comparable NPVs were found in Caucasians, and also at year three 
and five . Additionally, when cirrhotic and non-cirrhotic patients were studied separately, 
only GAG-HCC score remained predictive for the occurrence of an HCC.
Influence of etv treatment on HCC risk scores
Overall, predicted HCC risk based on CU-HCC, GAG-HCC and REACH-B declined after one 
year of ETV therapy, both in the overall population, as well as in cirrhotic, non-cirrhotic 
and Caucasian patients (all p-values < 0.001 for the change during follow-up with base-
line). The decline in HCC risk scores from baseline to year 1 was comparable in patients 
who developed HCC versus those who did not.(Figure 2) Furthermore, hazard ratios of 
the dynamic risks for development of an HCC by an HCC risk score measurement at a 
random visit were comparable with those at baseline (Table 4 vs. Figures 2A-C) Despite 
the observation that the mean calculated risk scores were consistently higher in patients 
who developed HCC, diagnostic performance remained suboptimal during treatment. 
Negative predictive values in all patients with a minimum of 4 years of follow-up for all 
risk scores at year 1 of therapy were more than 95% (CU-HCC 51/52, GAG-HCC 157/165 
and REACH-B 124/128) with a sensitivity of 11% (1/9) for GAG-HCC, 89% (8/9) for CU-HCC 
and 50% (4/8) for REACH-B. Comparable values were found in the Caucasian subpopula-
tion (Table 4) and also when using a single HCC risk score measurement at a random 
visit .
DIsCussIoN
In this European multicenter real-life cohort study we showed that CHB patients treated 
with ETV remain at considerable risk for developing HCC. The risk of HCC cannot be 
confidently predicted using HCC risk-scores at baseline nor during therapy, particularly 
not in Caucasians. Careful follow-up therefore remains necessary even if HBV DNA is 
adequately suppressed.
ETV therapy effectively suppresses viral replication, and in the current study virtually 
all patients achieved an undetectable HBV DNA during therapy. Recent studies have 
shown that a reduction of HBV DNA to low or undetectable levels reduces the risk of 
liver-related events and HCC.6-8 However, in the current study we were unable to confirm 
the association between time to and duration of viral suppression and a reduction in the 
incidence of HCC or clinical events. Our findings are in line with another large European 
study which also found considerable rates of HCC despite long-term viral suppression.13 
The reason for the differences between the Asian studies and those conducted in Europe 
are currently unclear, but may be accounted for by differences in HBV genotype distribu-
tion, time since infection, and previous treatment exposure in the Western cohorts.
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figure 2. A) CU HCC B) GAG-HCC and C) REACH-B risk scores over time with 95% CI by development of HCC 
during ETV treatment. HR represents the dynamic risks for development of an HCC by an HCC risk score 
measurement at a random visit. HR was corrected for duration of therapy and multiple visits per patient.
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Considering the residual risk of HCC even in patients with undetectable HBV DNA, 
careful monitoring remains of vital importance. A recent study from Hong Kong sug-
gests that previously identified risk scores for HCC in untreated patients may also be 
applied effectively in ETV treated subjects.9 We were unable to confirm these findings 
in our ethnically diverse cohort. While baseline GAG-HCC and CU-HCC risk scores were 
higher in patients that developed HCC, REACH-B scores offered little prognostic help. 
Furthermore, the discriminatory performance of the risk scores was limited by the low 
sensitivity observed in the overall population and mainly in the Caucasians. These find-
ings are of major clinical importance because they show that a considerable proportion 
of patients that will develop HCC is not identified using previously defined risk-score 
cut-offs. Moreover, this implies that there is little to no additional value of those HCC risk 
scores to the pre-existing life-time risk of HCC in CHB patients and the clinical relevance 
for daily practice of these risk scores remains disputable, particularly in Caucasian pa-
tients.
Given the fact that ETV effectively suppresses HBV DNA in the majority of patients after 
a single year of therapy, we considered applying the risk scores at various on-treatment 
time-points. While we observed a decline in the predicted risk of HCC over time, the 
patterns were comparable for patients who developed HCC compared to those who 
did not and predictive performance after one year was therefore comparable to that 
at baseline. Furthermore, HR did not alter over time when looking at the dynamic risks 
for development of an HCC by an HCC risk score measurement at a random visit. These 
findings suggest that there is little reason to continue calculating the risk-scores during 
therapy. However, studies with longer follow-up may be required to estimate the risk 
of HCC during therapy beyond 5 years. Despite our large cohort of CHB patients, our 
study was limited by the fact that we observed a limited number of HCC’s. Since the 
availability of ETV limits our duration of follow-up, future long-term follow-up may help 
us to understand the long-term effect of ETV on HCC risk. Furthermore, the risk of HCC in 
non-cirrhotic patients might be underestimated since screening may be less frequent or 
suboptimal when compared to the cirrhotic population. In conclusion, in this European 
multicenter real-life cohort study we showed that continuous ETV therapy effectively 
suppresses HBV DNA in the vast majority of patients. While the risk of HCC in ETV treated 
patients is low through up to five years of treatment, ETV therapy does not eliminate the 
risk of HCC. Previously described risk-scores for HCC have limited sensitivity for HCC in 
Caucasian patients and do not appear to be clinically useful either at baseline nor during 
therapy. Screening of risk groups therefore remains necessary despite successful ETV 
therapy, at least during the first years of treatment.
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Early hepatic flares during ETV treatment are 
rare and do not require treatment adaptation 
in chronic hepatitis B without cirrhosis
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ABstrACt
Background
Flares during NA therapy are usually associated with antiviral resistance or cessation of 
therapy. Since ETV resistance is rare and therapy is rarely stopped, we investigated the 
frequency and outcome of flares during ETV therapy in CHB.
methods
All HBV monoinfected patients treated with ETV from 11 large European centers (VIRGIL 
Study Group) were studied. Flares were defined as an ALT level >3x compared to baseline 
with an absolute ALT level > 3xULN.
results
A total of 733 patients were treated for a median of 168 (IQR 84-213) weeks with ETV 
monotherapy. Nineteen patients (3%) developed a flare after a median of 26 (10-83) 
weeks. None of the patients developed genotypic resistance and in only one case 
non-compliance was documented. Flares were relatively mild with a median ALT peak 
of 7.3xULN (IQR 4.5-10-1). Among patients with flares, one developed HBeAg serocon-
version, and one lost HBeAg. Baseline HBeAg status (HR 2.91, 95%CI 1.17-7.23, p=0.02), 
HBV DNA (HR 1.31, 95%CI 1.06-1.63, p=0.01), platelet count (HR 0.99, 95%CI 0.98-1.00, 
p=0.04) and albumin (HR 0.91, 95%CI 0.84-0.99, p=0.03) were associated with develop-
ment of a flare. Nine patients (47%) had a flare which was associated with a decline in 
HBV DNA, three patients (16%) with a stable HBV DNA and seven (37%) with an increase 
in HBV DNA. Flares associated with a decline in HBV DNA occurred after a median of 10 
weeks (IQR 4-21), which was significantly earlier compared to flares associated with a 
stable or increase in HBV DNA (76 weeks, IQR 29-149) (p<0.001).
Conclusion
Flares during ETV are rare. Flares in patients without cirrhosis and flares occurring before 
week 26 of therapy were almost exclusively present during continued decline of HBV 
DNA. In these patients ETV can be continued under strict monitoring as the majority 
have a good biochemical- and virologic outcome.
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INtroDuCtIoN
Approximately 400 million people worldwide are chronically infected with the hepatitis 
B virus (HBV), which can lead to progression of liver diseases with increased risk of cir-
rhosis, liver failure, and hepatocellular carcinoma.1
Currently, peg-interferon (PEG-IFN), tenofovir (TDF) and entecavir (ETV) are first line 
treatment options for chronic hepatitis B (CHB) infections.2,3 During IFN therapy, flares 
of inflammatory activity are often observed. These flares are the result of an increase 
in particular cytotoxic T lymphocytes, which are important to control HBV but can also 
induce liver damage, depending on the environment and functional capability, result-
ing in intrahepatic necroinflammation.4,5 Flares during IFN treatment can be severe, but 
have also been associated with virologic response.6 Flares during nucleos(t)ide analogue 
therapy are rare and are mostly associated with antiviral resistance, cessation of therapy 
or non-compliance to therapy.7,8
ETV is a cyclopentyl guanosine analogue and showed superior biochemical, virologi-
cal and histological efficacy and HCC-free survival compared to lamivudine (LAM).9-13 
Moreover, genotypic resistance to ETV is rare in NA-naïve patients through five years 
of continuous therapy.14 Current guidelines recommend long-term continuation of ETV 
treatment, unless there is genotypic resistance or if HBsAg loss occurs. Therefore, therapy 
is rarely stopped. However, it is unclear whether treatment adaptation is necessary for 
patients who develop a flare during ETV treatment. The aims of this cohort study were 
to investigate the frequency and outcome of on-treatment flares during ETV therapy in 
CHB patients.
metHoDs
study population
Within this investigator-initiated cohort study within the European network of excel-
lence for Vigilance against Viral Resistance (VIRGIL) we studied all consecutive CHB 
patients (HBsAg positive for at least 6 months) treated with ETV monotherapy for at least 
3 months between 2005 and April 2013 from 11 large European referral centers. Patients 
were excluded if they were co-infected with HIV, HCV or HDV or if they had an HCC at 
baseline. A total of 733 patients were eligible for analysis. The study was conducted in 
accordance with the guidelines of the Declaration of Helsinki and the principles of Good 
Clinical Practice. Patients gave written informed consent according to standards of the 
local ethics committees.
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follow-up of participants
All subjects were prospectively monitored two to four times a year at the discretion of the 
local treating physician. At every visit routine examination with biochemical (serum alanine 
aminotransferase (ALT), bilirubin and albumin, international ratio (INR) of prothrombin time) 
and virologic (Hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), antibody 
against HBeAg (anti-HBe), HBV DNA level) assessments took place. The diagnosis of cirrhosis 
at baseline was based on histology or ultrasound examinations with signs of cirrhosis (spleen 
size >12 cm, portal vein>16 mm, or nodules within the hepatic parenchyma).
endpoints
The primary outcome was the occurrence of a flare. Transaminases were assessed lo-
cally and expressed as values representing a ratio to the local upper limit of normal 
(xULN). In accordance with Flink 6 a flare was defined as a threefold increase in serum ALT 
compared with baseline levels with an absolute ALT level > 3xULN. Secondary endpoints 
were virologic response, (HBV DNA levels < 80 IU/mL), HBeAg loss (in HBeAg-positive 
patients) and HBsAg loss during the on-treatment follow-up period.
Laboratory tests
Serum ALT, bilirubin, albumin levels and INR of prothrombin time were measured lo-
cally using standardized automated techniques. HBsAg, HBeAg and anti-HBe were 
determined using commercially available enzyme immunoassays in all centers. Serum 
HBV DNA levels were measured using a quantitative real-time polymerase chain reac-
tion assay, the COBAS AmpliPrep-COBAS TaqMan HBV test (CAP-CTM; Roche Molecular 
Systems, Inc., Branchburg, NJ, USA), with a lower limit of detection of 12 IU/mL, in ten of 
eleven centers. In one center serum HBV DNA was measured using Roche Amplicor (lin-
ear dynamic range, 400 to 200,000 copies/mL; Roche Diagnostic Systems, Branchburg, 
NJ, USA). A conversion factor of 5.26 copies/IU was used for conversion of copies/mL to 
IU/mL. HBV genotypes and detection of HBV polymerase gene mutations was deter-
mined by direct sequencing or using the INNO-LiPA assay (Innogenetics, Gent, Belgium).
Data analysis
Data were systematically collected from the patients’ charts through a standardized 
clinical research form by one investigator (PA). HBV DNA levels were logarithmically 
transformed. ALT levels are expressed as values representing a ratio to the local ULN. 
Continuous variables are expressed as means ± SD or median (IQR). Cox’s regression 
analysis was used to study which factors were associated with primary or secondary 
endpoints. All statistical tests were two-sided, and a P value < 0.05 was considered to 
be statistically significant. SPSS version 20.0 (SPSS Inc., Chicago, IL, USA) and SAS 9.2 
program (SAS Institute Inc., Cary, NC, USA) were used for all statistical analysis.
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resuLts
Baseline characteristics
A total of 733 CHB patients treated with ETV monotherapy were included. Baseline char-
acteristics of the study population according to the occurrence of a flare are shown in 
Table 1. Overall, median follow-up was 168 (IQR 84-213) weeks (154 weeks (IQR 93-258) 
for patients who developed a flare and 168 (IQR 83-212) weeks for patients without a 
flare). At baseline 234 patients (32%) were HBeAg positive, median ALT was 1.4 x ULN 
(IQR 0.8 – 2.7) and mean HBV DNA 5.3 ± 2.2log IU/ml. Two flare patients had NASH at 
baseline and none of those had a history of excessive alcohol abuse. Six patients had a 
BMI > 25, three patients < 25 and BMI was unknown in ten cases.
virologic and serologic response during treatment
Virologic response (HBV DNA < 80 IU/mL) was achieved in 642 patients (88%). The cu-
mulative probability of virologic response was 52.5%, 75.4%, 89.6%, 94.4% and 98.8% 
at six months and years 1, 2, 3 and 5, respectively. Virologic response was influenced by 
baseline HBV DNA (HR 0.77; 95%CI 0.74-0.80; p<0.001) and HBeAg status (HR 0.39; 95% 
CI 0.33-0.47l p<0.001), but not by baseline ALT (p=0.62). HBeAg loss was achieved in 
83 (36%) of 233 HBeAg-positive patients. The cumulative probability of HBeAg loss was 
11.2%, 24.8% and 35% at years 1, 2 and 3 and was influenced by ALT at baseline (HR 1.05; 
95% CI 1.03-1.08, p<0.001), but was not associated with baseline HBV DNA (p=0.57). 
Fifteen patients (2%) achieved HBsAg loss.
Biochemical response during treatment
At baseline, 451 patients had an ALT level above the upper limit of normal. During 
follow-up biochemical response (normalization of ALT) was achieved in 378 of those 451 
patients (84%) after a median duration of 24 weeks (IQR 13-49). The cumulative prob-
ability of biochemical response was 47%, 66%, 80%, 88%, 90% and 96% at six months 
and years 1, 2, 3, 4 and 5, respectively. Biochemical response rates were influenced by 
baseline HBeAg status (HR 0.70, 95% CI 0.56-0.86, p=0.001), and baseline ALT (HR 1.03, 
95% CI 1.01-1.04, p<0.001), but not by HBV DNA (HR 0.99, 95% CI 0.95-1.05, p=0.92).
Among the total population 659 patients (90%) achieved or maintained an normal ALT 
level after a median duration of 25 weeks (IQR 0-32). Two hundred and two HBeAg posi-
tive patients (87%) achieved biochemical response (median 26 weeks, IQR 4-53) and 457 
HBeAg negative patients (91%) achieved biochemical response (median 11 weeks, IQR 
0-24). Biochemical response rates in the total population were influenced by baseline 
HBeAg status (HR 0.67, 95% CI 0.57-0.79, p<0.001), and HBV DNA (HR 0.91, 95% CI 0.88-
0.94, p<0.001), but not by baseline ALT (HR 0.99, 95% CI 0.98-1.01, p=0.47)
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ALt flares
Nineteen patients (3%) developed a flare (ALT > 3x ULN compared to baseline ALT, and an 
absolute ALT level >3xULN) after a median of 26 (10-83) weeks. The flares were relatively 
mild with a median ALT peak of 7.3 (IQR 4.5-10.1) xULN. Of the 19 flare patients, eight pa-
tients had a flare with an ALT level between 5-10x ULN and six patients with an ALT level 
> 10x ULN. In univariate cox regression analysis, baseline HBeAg status (HR 3.66, 95%CI 
1.44-9.29, p=0.01), HBV DNA level (HR 1.31, 95%CI 1.06-1.63, p=0.01), platelet count (HR 
1.0, 95%CI 0.98-1.00, p=0.04) and albumin level (HR 0.91, 95%CI 0.84-0.99, p=0.03) were 
associated with development of a flare. Other baseline characteristics (including ALT 
level, age and presence of cirrhosis) were not associated with the development of a flare 
table 1. Baseline characteristics
All (n=733) Flare (n=19) No flare (n=714)
Male (%) 562 (77%) 16 (84%) 546 (77%)
Mean age 44 ± 14 41 ± 11 44 ± 14
Race
Caucasian 313 (43%) 11 (58%) 302 (42%)
Asian 209 (29%) 5 (26%) 204 (29%)
African 137 (19%) 1 (5%) 136 (19%)
Missing 74 (10%) 2 (11%) 72 (10%)
Genotype
A 99 (14%) 5 (26%) 94 (13%)
B 47 (6%) 1 (5%) 46 (6%)
C 77 (11%) 2 (11%) 75 (11%)
D 185 (25%) 7 (37%) 178 (25%)
E 50 (7%) 0 (0%) 50 (7%)
other 5 (7%) 1 (5%) 3 (1%)
unknown 270 (37%) 3 (16%) 268 (38%)
Cirrhosis 163 (22%) 6 (32%) 157 (22%)
HBeAg positive 233 (32%) 12 (63%) 222 (32%)
Mean HBV DNA (log IU/mL) 5.3 ± 2.2 6.6 ± 2.1 5.2 ± 2.2
Median ALT (ULN) 1.4 (0.8-2.7) 1.3 (1-2.1) 1.4 (0.8-2.8)
Platelet count (x10E9/L) 192 ± 72 153 ± 63 194 ± 72
Median bilirubin (umol/L) 11 (8-15) 9 (8-17) 11 (8-15)
Albumin (g/dL) 43 ± 5 41 ± 6 43 ± 5
PT INR 1.1 ± 0.2 1.1 ± 0.2 1.1 ± 0.2
NA-naive 561 (77%) 12 (63%) 549 (77%)
LAM-naive 610 (83%) 15 (79%) 595 (83%)
IFN-naive 600 (82%) 18 (95%) 582 (82%)
Data are represented as mean (± standard deviation) or median (IQR). 
Risk and outcome of flares during entecavir treatment 83
(Table 2). The cumulative probability of a flare was 3.5%, 4.5% and 8.3% at years 1, 3 and 
5 for HBeAg positive versus 0.6%, 1.7% and 1.7% for HBeAg negative patients (p=0.003; 
Figure 1). Probability of a flare was not influenced by previous therapy. Poor adherence 
to ETV therapy was only documented in one flare patient.
table 2. Baseline factors associated with a flare
Flares (n=19)
Risk factor HR 95%CI p
Age (per year) 0.99 0.95-1.02 0.47
Female 0.58 0.17-2.00 0.39
Caucasian 0.55 0.26-1.15 0.11
Genotype B 0.93 0.66-1.33 0.70
HBeAg pos 3.66 1.44-9.29 0.01
HBVDNA(log IU/ml) 1.31 1.06-1.63 0.01
ALT (xULN) 0.94 0.78-1.12 0.47
Bilirubin (umol/L) 1.00 0.99-1.01 0.38
Albumin (g/dL) 0.91 0.84-0.99 0.03
INR 2.07 0.20-22.04 0.55
Platelet count (x10E9/L) 1.0 0.98-1.00 0.04
Cirrhosis 1.54 0.58-4.06 0.38
Previous NA 0.54 0.21-1.36 0.19
Previous LAM 1.22 0.41-3.69 0.72
Previous IFN 0.23 0.03-1.73 0.15
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figure 1. Kaplan-Meier curve for the probability of achieving an ALT flare according to HBeAg status at 
baseline.
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ALt flares and outcome
Figure 2 shows individual HBV DNA and ALT levels during ETV therapy of six patients who 
developed a flare. Overall, nine patients (47%) had a flare associated with a decline in 
HBV DNA, three patients (16%) with a stable HBV DNA and seven (37%) with an increase 
in HBV DNA. One patient with HBV DNA decline also achieved HBeAg seroconversion and 
one patient with HBV DNA increase achieved HBeAg loss. Of the patients with a stable 
C
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F
figure 2 Kinetics of HBV DNA and ALT levels in six patients who developed a flare during ETV treatment.
--- = ALT levels (xULN); - - - = HBV DNA (log IU/mL);
A-C) HBV DNA decline; C) achieved HBeAg seroconversion; D) HBV DNA stable; developed hepatic decom-
pensation and died consequently; E) HBV DNA increase, achieved HBeAg loss; F) HBV DNA increase, poor 
compliance
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HBV DNA, one patient developed an HCC and two patients developed decompensated 
cirrhosis and died consequently. All three patients had cirrhosis at baseline. (Table 3)
Flares associated with a decline in HBV DNA occurred after a median of 10 weeks (IQR 
4-21), which was significantly earlier compared to flares associated with a stable or 
increase in HBV DNA (76 weeks, IQR 29-149) (p<0.001). Moreover, patients with a flare 
table 3. Characteristics of all 19 patients who developed a flare
Flare 
week
PEAK ALT 
(xULN)
Cirrhosis HBeAg Viral load
ALT 
normalization
Virologic 
response
Remarks
4 10.1 No Pos
HBV DNA 
decline
Yes No
4 7.7 No Pos
HBV DNA 
decline
Yes Yes
15 14.0 No Pos
HBV DNA 
decline
Yes No
15 13.0 Yes Pos
HBV DNA 
decline
Yes Yes
10 4.5 No Neg
HBV DNA 
decline
Yes Yes
4 8.5 No Neg
HBV DNA 
decline
Yes Yes
53 3.2 No Pos
HBV DNA 
decline
Yes Yes
4 8.2 No Pos
HBV DNA 
decline
Yes Yes
26 8.4 Yes Pos
HBV DNA 
decline
Yes Yes HBeAg SC week 54
67 6.7 Yes Pos
HBV DNA 
stable
No No HCC week 21
223 5.8 Yes Pos
HBV DNA 
stable
No No
Decomp + death 
week 222
124 44.3 Yes Neg
HBV DNA 
stable
No No
Decomp + death 
week 117
83 4.7 No Neg
HBV DNA 
increase
Yes Yes Poor compliance
100 3.7 No Neg
HBV DNA 
increase
Yes Yes
12 3.7 No Neg
HBV DNA 
increase
Yes Yes
30 16.9 No Pos
HBV DNA 
increase
Yes Yes
234 5.5 Yes Pos
HBV DNA 
increase
Yes No
23 3.6 No Pos
HBV DNA 
increase
Yes Yes HBeAg loss week 39
69 7.3 No Neg
HBV DNA 
increase
Yes Yes
86 Chapter 5
within 26 weeks of treatment were more likely to have a flare associated with a decline in 
HBV DNA, compared to patients with a flare after 26 weeks (78% vs 20%, p=0.02).
The cumulative probability of virologic response was comparable between patients 
with or without a flare (p=0.09). Also in a cox regressions analysis with virologic response 
as a time-dependent factor HBV DNA decline was not associated with the development 
of a flare (HR 0.43; 95%CI 0.13-1.43; p=0.17).
Sixteen patients (84%) achieved ALT normalization after the flare. All three patients who 
were not able to achieve ALT normalization had cirrhosis at baseline, compared to only 
three patients (19%) who achieved ALT normalization (p= 0.02). After the flare, 13 (68%) 
patients achieved HBV DNA undetectability without treatment adaptation; one of them 
achieved HBsAg loss. Three patients died, two because of decompensation and one 
because of gastric cancer. One patient was switched to TDF therapy with good response. 
None of the patients developed ETV resistance.
DIsCussIoN
In our cohort of 733 CHB patients treated with ETV we showed that the risk of a flare is 
low, with an overall cumulative probability of 4% at year 5 of therapy. Patients who were 
HBeAg positive and patients with a higher viral load or lower albumin or platelet level 
at baseline were more susceptible to developing flares. Interestingly, flares in patients 
without cirrhosis and flares occurring before week 26 of ETV therapy were almost exclu-
sively present during continued decline of HBV DNA.
Flares are the result of an increase in intrahepatic necroinflammation associated with 
expanded numbers of intrahepatic lymphocytes.4,5 They may be observed both sponta-
neously, as well as during treatment. Previous studies have described flares during LAM 
therapy. Those flares were mostly caused by viral resistance in which case LAM had to be 
discontinued and patients had to be switched to other antiviral treatment regimens.8,15 
Nevertheless, flares do not occur more often in NA treated patients than in the natural 
course of CHB 8 or perhaps even less often.15 In addition to Manns et al we found that 
only 3% of all ETV treated patients developed a flare.16
Flares during (PEG-)IFN treatment have been associated with virologic and serologic 
response, with a good clinical outcome.6 In the study of Manss et al it appeared that 
most flares during ETV treatment were also associated with a reduction in HBV DNA.16 
Nevertheless, we showed a more distinct pattern of the flares which could be associated 
with either a decline or increase in HBV DNA levels. Flares occurring before week 26 
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of ETV therapy were almost exclusively present during continued decline of HBV DNA. 
However, late flares were more often associated with an increase in HBV DNA and con-
sequent unfavorable treatment outcome, such as decompensation and death. Only two 
(11%) of the flare patients achieved either HBeAg loss or seroconversion.
Hence, it remains very questionable whether flares during NA therapy can be compared 
with flares during (PEG-)IFN treatment.
Development of resistance during treatment with NA - resulting in an increase in HBV 
DNA levels with or without an increase in ALT levels - has been associated with an ad-
verse treatment outcome.17-19 Therefore, EASL guidelines suggest treatment adaptation 
in these patients.2 However, resistance to ETV is rare through five years of continuous 
therapy.14 In our study none of the patients who developed a flare did develop genotypic 
resistance. However, an increase in HBV DNA was observed in some patients, possibly 
through unknown non-compliance. Nevertheless, in our study poor adherence to ETV 
therapy was only documented in one patient.
Increase in ALT levels can occur because of several other causes, such as hepatitis A, 
hepatitis E, autoimmune hepatitis and excessive alcohol consumption and non-alcoholic 
steatohepatitis (NASH). However, only few patients had a high BMI or NASH and none of 
the patients had a history of excessive alcohol abuse. Since the flares were rather mild, 
most patients were not tested for other (acute) liver diseases.
Interestingly, patients who were HBeAg positive and patients with a higher viral load or 
lower albumin or platelet level at baseline were more susceptible to developing flares. 
HBeAg positivity has been related to development of flares in the natural course of 
CHB.8 However, it is not clear why low albumin and platelet levels are associated with 
an increased risk of a flare. Possibly, this can be explained by the fact that these patients 
were also more likely to have (beginning) cirrhosis and thus are more prone to develop 
decompensated liver disease.
In conclusion, our study showed that ALT flares during ETV are rare. Flares occur more 
frequently in patients who are HBeAg positive and patients with a higher viral load or 
lower albumin or platelet level at baseline. Flares in patients without cirrhosis and flares 
occurring before week 26 of ETV therapy were almost exclusively present during con-
tinued decline of HBV DNA. We therefore recommend to continue ETV therapy in these 
patients as the majority have a good biochemical- and virologic outcome. Furthermore, 
the importance of treatment compliance should be stressed to all HBV patients on oral 
anti-HBV agents.
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ABstrACt
Background and aims
Real-life prospective data on adherence to nucleos(t)ide analogues (NA) in chronic 
hepatitis B patients (CHB) are scarce. We investigated adherence to entecavir (ETV) 
therapy in relation to viral response.
methods
We provided 100 consecutive CHB patients with a medication dispenser that monitors 
ETV intake real time during 16 weeks therapy. HBV DNA was measured at baseline and 
at the end of the study. Quality of life (SF-36) and beliefs about medicines (BMQ) were 
evaluated using questionnaires.
results
Adherence over 16 weeks averaged 85±17%, with 70% of patients exhibiting ≥80% (i.e. 
good) adherence. Maximum time between two consecutive doses was 3 days (median, 
range 1-53 days). Patients with <80% (i.e. poor) adherence were significantly younger 
(p=0.01). An accepting attitude towards ETV was associated with good adherence while 
an indifferent attitude was associated with poor adherence (p=0.03). Viral breakthrough 
did not occur during the study period. Mean adherence in patients with HBV DNA after 
16 weeks >20 IU/mL and ≤20 IU/mL (n=18 and n=81 respectively) was 83% and 91% 
respectively (p=0.19). In multivariate analysis, adherence was not a significant predictor 
of HBV DNA negativity (adjusted OR 1.02 (95% CI 0.98-1.07), p=0.34), after adjustment 
for duration of ETV treatment (adjusted OR 18.8, p<0.001) and HBeAg status (adjusted 
OR 11.9, P=0.001).
Conclusions
Seventy percent of our CHB patients exhibited good adherence to ETV therapy, with 
younger patients and those with an indifferent attitude being more prone to poor ad-
herence. Poor adherence was not an independent predictor of virologic response.
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INtroDuCtIoN
Chronic hepatitis B (CHB) infection is a worldwide problem with approximately 350 
million people being chronically infected.1,2 Although most CHB patients remain 
asymptomatic, patients are at risk of developing cirrhosis, hepatic decompensation 
and hepatocellular carcinoma.3 Antiviral treatment with nuleos(t)ide analogues (NA) 
may enhance survival by preventing progressive disease.4 NA are administered orally 
and have minimal side effects. Since they generally do not eradicate but only suppress 
hepatitis B virus (HBV), the large majority of patients requires long-term and possibly 
lifelong treatment.
Treatment failure in CHB patients on NA is uncommon. Virologic breakthrough, defined 
as re-appearance of HBV DNA at levels at least 10-fold higher than the lower limit of 
detection after achievement of undetectable HBV DNA or HBV DNA increase by >1 
log from nadir, is generally the first clinical manifestation of treatment failure. During 
long-term follow-up of registration studies of currently available highly potent NA 
such as entecavir (ETV) or tenofovir (TDF), emerging resistance was low or absent.5-7 
It has recently been suggested that in addition to genotypic viral resistance, patient 
non-adherence is a major cause of treatment failure.8-10 Poor adherence to long-term 
treatment for other chronic diseases such as hypertension or hypercholesterolemia is a 
frequent phenomenon, especially in asymptomatic patients.11,12 It has also been shown 
that adherent patients on antihypertensive or anti-HIV medication are less likely to have 
suboptimal treatment responses.13-16 Since CHB patients generally are asymptomatic, 
adherence to long-term antiviral treatment could also be suboptimal in these patients. 
Nevertheless, only few studies have investigated adherence to NA. Since no reliable as-
says are currently available to determine ETV plasma levels, one needs to rely here on 
alternative methods. Previous studies have either used pharmacy refill claims or patients 
self-report to measure adherence. Nevertheless, pharmacy claims provide only a gross 
estimation of patient adherence, whereas patient- and especially physician-reported 
adherence rates are well known to overestimate adherence considerably.17 In contrast, 
real time medication intake monitoring is the most reliable new methodology currently 
available to assess patient adherence.
The aim of the current prospective, open-label study was therefore to evaluate adher-
ence rates in 100 CHB patients on ETV treatment using real time medication monitoring. 
Furthermore, we aimed to relate adherence to HBV DNA levels and evaluate potential 
risk factors for suboptimal adherence.
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metHoDs
study population
All consecutive adult CHB patients treated with ETV (indications according to EASL 
guidelines18) at two academic hospitals in the Netherlands were asked to participate in 
the study. Both naive and treatment-experienced patients were allowed to participate, 
as well as patients with impaired renal function requiring dose reduction of ETV and 
patients receiving ETV as prophylaxis during chemotherapy or immunosuppressant use. 
Patients co-infected with HIV, patients without understanding of Dutch or English lan-
guage and patients unable to provide written informed consent were not eligible for the 
study. This study was conducted in accordance with the guidelines of the Declaration of 
Helsinki and the principles of Good Clinical Practice. All patients gave written informed 
consent according to standards of the local ethics committees.
study design
All consecutive CHB patients visiting the outpatient clinic of two academic hospitals in 
the Netherlands between December 2011 and August 2012 were asked to participate in 
this prospective, open-label study. After written informed consent, patients received a 
Sensemedic medication dispenser which monitored medication intake during at least 
16 weeks. Patients were asked to fill out a questionnaire at baseline and at one follow-up 
visit (end of study). At both baseline and end of study visits, routine laboratory tests 
(including full blood count, ALT, albumin, creatinine) as well as quantitative serum HBV 
DNA testing (Cobas Taqman, Roche diagnostics, Almere, the Netherlands: real-time PCR, 
lower limit of detection 20 IU/mL) were performed. Also, charts of the patients were re-
viewed to extract data on HBV (treatment) history, duration of ETV therapy, (psychiatric) 
co-morbidities, number of concomitant drugs and (previous) substance abuse.
sensemedic dispenser
The Sensemedic medication dispenser (Evalan, Amsterdam, the Netherlands, https://
real.evalan.com/sensemedic_research), monitors medication intake real-time; when the 
patient opens the dispenser, data are directly transferred to a central server. Adherence 
data were available for the investigators through a secured internet account. However, 
there was no intervention by the study team when the patient did not open the dis-
penser. Patients used the Sensemedic medication dispenser until the next scheduled 
visit to the out-patient clinic department, with a minimum period of 16 weeks.
We assumed all patients used the Sensemedic medication dispenser during the total 
study period of 16 weeks. When no opening of the Sensemedic dispenser was regis-
tered on a study day, this was classified as non-adherence. When two openings of the 
Sensemedic dispenser were registered on the same day, this was classified as one intake 
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unless no intake was registered on the previous day and consecutive doses on the same 
day were ≥12 hours apart. We assumed in this situation, that the patient forgot the first 
ETV dose, but catched up the next day.
Questionnaires
Patients were asked to fill out a questionnaire at baseline and at the follow-up visit. 
The baseline questionnaire contained questions on demographics, education, side ef-
fects of ETV, and quality-of-life. The follow-up questionnaire also contained questions 
on patients’ beliefs about medicine, self-reported adherence and patient experiences 
regarding the Sensemedic system.
Quality of life was assessed using the validated medical outcomes Study 36-item Short-
Form General Health Survey (SF-36).19 The SF-36 is composed of 36 questions, and 
contains four domains in the area of physical health (Physical Component Summary) 
and four domains in the area of mental health (Mental Health Summary). SF-36 scores 
range from 0 to 100, with higher scores indicating better health.
The Beliefs About Medicines Questionnaire (BMQ) consists of two sections: the BMQ-
Specific assesses beliefs about the necessity of a specific medication and concerns about 
the potential adverse effects whereas the BMQ-General assesses beliefs about the harm-
fulness and overuse of medicine in general.20 The BMQ uses a 5-point Likert scale rang-
ing from strongly disagree (=1) to strongly agree (=5). The BMQ-Specific comprises two 
5-item scores (Necessity and Concerns), the BMQ-General has two 4-item scores (Harm 
and Overuse). Mean scores for each subscale were calculated with scores ranging from 
1 to 5. According to the balance between scores for Necessity and Concerns, patients 
can be subdivided into 4 attitudinal groups.21 Self-reported adherence was measured 
using the Medication Adherence Report Scale (MARS)20, which is a brief self-report 
instrument, assessing five separate non-adherent behaviors using a 5-point Likert scale. 
Scores of the separate items are summed, scores can range from 5 to 25 with higher 
scores representing higher levels of self-reported adherence. The BMQ and the MARS 
questionnaires have been used and validated in patients with various chronic diseases, 
including asthma, HIV, inflammatory bowel disease and psychiatric illnesses.21-24
Definitions and endpoints
The primary endpoint of the study was adherence to ETV during 16 weeks. Adherence 
was expressed as percentage and calculated using the formula: (no. of treatment days 
– no. of missed doses) / no. of treatment days. The total study period was divided in 4 
periods of 4 weeks to investigate whether adherence changed over time. Patients were 
subdivided into two groups (good adherence vs. poor adherence) using a cut-off of 80% 
adherence.25 Secondary endpoints of the study were the maximum number of days 
without any dose and the virologic response of the patients (HBV DNA levels).
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statistics
Baseline characteristics of adherent vs. non-adherent patients as well as patients with 
or without adequate virologic response were compared using the Student’s t-test or 
Mann Whitney-U test for continuous variables and the chi-square test for dichotomous 
variables. Potential risk factors for inadequate virologic response were evaluated by 
multivariate logistic regression analysis. Factors with a p-value <0.2 in univariate analy-
sis were entered in a subsequent multivariate analysis. IBM SPSS Statistics, version 20.0.0 
(IBM, Armonk, New York, United States) was used for statistical analysis. A two-sided 
p-value <0.05 was considered statistically significant.
resuLts
Baseline characteristics
One hundred thirty-six consecutive CHB patients on ETV treatment were asked to par-
ticipate in this study. Of those, 100 patients provided written informed consent. Reasons 
for not participating in the study were unwillingness to participate in a research project 
(n=15), unwillingness to use the Sensemedic medication dispenser (n=13) and language 
discordance (n=8). Baseline and treatment history characteristics of the 100 included 
patients are given in Table 1, whereas treatment history characteristics are summarized 
in Table 2. Mean age of the patients was 45 years, with the vast majority of patients be-
ing male and often of Asian origin. Twenty-nine percent of patients exhibited cirrhosis, 
based on liver biopsy, transient elastography (Fibroscan®, Echosens, Paris, France) and/
or abdominal ultrasound and 27% of patients were treated with any other NA before 
start of ETV. At inclusion in the study 64% of patients were HBeAg negative and 67% had 
been treated with ETV for at least one year.
Adherence
Adherence of the 100 included patients during the total study period of 16 weeks av-
eraged 85 ± 17%, with a median of 91% (range 25-100%). The percentage of patients 
with ≥70%, ≥80%, ≥90%, ≥95% and ≥99% adherence was 81%, 70%, 52%, 43% and 25% 
respectively (Figure 1A). The maximum time between two consecutive doses was 3 days 
(median, range 1-53 days) (Figure 1B), which correlated with overall adherence (Spear-
man’s ρ -0.87, p<0.001). As shown in Figure 2, adherence decreased over time.
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table 1. Characteristics of 100 CHB patients on entecavir treatment.
BAseLINe CHArACterIstICs Chronic hepatitis B
(n=100)
male gender 76%
mean age, years ±sD (range) 45 ± 14 (18-80)
Body weight, kg ±sD (range) 75 ± 15 (44-130)
Presence of cirrhosis 29%
result most recent fibroscan®#
  f0-f1, n 33 (48%) 
  f2, n 20 (29%) 
  f3, n 6 (9%) 
  f4, n 10 (14%) 
years since diagnosis HBv, median [IQr] 8 [3 – 13]
HBe negativity
  Before initiation of treatment 51% 
  At start of study 64% 
elevated Ast and/or ALt 31%
HBv genotype
  A 18% 
  B 11% 
  C 14% 
  D 20% 
  other / unknown 37% 
mode of transmission
  vertical 29% 
  sexual 13% 
  other / unknown 58% 
≥1 co-morbidity 54%
  gastro-intestinal / hepatobiliary disease 19% 
  Hypertension 15% 
  Cardiovascular disease 11% 
  Diabetes mellitus 10% 
  Hepatocellular carcinoma 6% 
  other malignancy 8% 
  renal insufficiency 5% 
History of depression / psychiatric illness 17%
Number of concomitant oral medications
  ≥1 47% 
 median [IQr]* 2 [1 – 6] 
History of i.v. drug use 0%
Current alcohol use >5 units/week 11%
# based on the 69 patients with Fibroscan® result
* based on the 47 patients with ≥1 oral medication
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Questionnaires
Results of the questionnaires are given in Table 3. Patients reported a median adherence 
score of 24 on the MARS scale (range 15-25), which correlated with adherence as mea-
sured by the electronic medication dispenser (Spearman’s ρ 0.37, p=0.003). However, 
self-reported adherence was higher than adherence as measured by the electronic dis-
penser. Sixty-seven percent of patients said that their adherence to ETV did not change 
since they started using the Sensemedic dispenser and 52% of patients believed that 
the Sensemedic medication dispenser could be useful for other patients.
According to the BMQ Specific questionnaire, virtually all patients (94%) had strong 
beliefs in the necessity of ETV treatment for maintaining their health. However, most 
patients (59%) had also strong concerns about the potential adverse effects of ETV. 
When patients were categorized into the 4 attitudinal groups, 59% of patients were 
“ambivalent” (high necessity, high concerns), 35% were “accepting” (high necessity, low 
concerns), 6% was “indifferent” (low necessity, low concerns) and none of the patients 
was “sceptical” (low necessity, high concerns). When asked about medication in general, 
55% of patients had strong beliefs about the harmfulness of medicines and 79% of 
patients had strong beliefs about the overuse of medicines.
Predictors of poor adherence
In univariate analysis (Table 4) a significant association between age and percentage of 
patients with less than 80% adherence was found with younger age being associated 
with poor adherence (p=0.01). Furthermore, an “accepting” attitude towards ETV was 
table 2. Treatment characteristics of 100 patients with chronic HBV infection on entecavir therapy.
treAtmeNt HIstory
Previous HBv treatment
 (Peg-)interferon 29% 
  Any NuC 27% 
  Lamivudine 19% 
  Adefovir 16% 
  tenofovir 6% 
Duration of entecavir treatment
  months, median [IQr] 24 [5 – 48] 
  ≥1 year 67% 
Indication for entecavir treatment
  therapeutic 96% 
  Prophylactic 4% 
entecavir dose
  0.5 mg/day 87% 
  1.0 mg/day 8% 
  other$ 5% 
$ dose adjustment due to renal insufficiency
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figure 2. Trends in entecavir adherence during 16 weeks of follow-up
Boxes represent the inter-quartile range (IQR): the boundaries of the box indicate the 25th and the 75th 
percentile, the horizontal line in the middle of the box represents the median. The vertical lines from the 
ends of the box indicate the highest respectively lowest value observed within 1.5 IQR, circles represent 
outliers.
 
figure 1A. Adherence in 100 CHB patients during entecavir therapy
The bar indicating 90-100% adherence is divided into a part with horizontal stripes (90-95% adherence 
(n=9)), a part with vertical stripes (95-99% adherence (n=18)) and a part with dots (99-100% adherence 
(n=25)).
 figure 1B. Maximum interval between two consecutive entecavir doses
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significantly associated with good adherence (≥80%) whereas patients with an “indif-
ferent” attitude were more prone for poor adherence (<80%) (p=0.03). No significant 
differences in gender, comorbidities, previous HBV treatment history, duration of ETV 
treatment, quality of life and any other covariates were observed between patients with 
good and poor adherence. In multivariate analysis, both age (adjusted OR 1.03, 95% 
CI 0.99 – 1.07, p=0.18) and attitude towards ETV (p=0.12 for total subgroup) were no 
independent predictors of poor adherence.
virologic response
One patient died after the follow-up period of 16 weeks but before HBV DNA measure-
ment due to myocardial infarction following elective coronary artery stent placement and 
could therefore not be included in the analysis regarding virologic response. Of the 99 
patients with HBV DNA results after 16 weeks, 66 patients (67%) had undetectable HBV 
table 3. Questionnaire results of 100 CHB patients on entecavir treatment
Chronic hepatitis B
(n=100)
Quality of life (sf-36) Median [IQR]
 Physical functioning 85 [50-95] 
 social functioning 75 [50-88] 
 role-physical 100 [50-100] 
 role-emotional 100 [0-100] 
 mental health 68 [52-80] 
 vitality 50 [35-65] 
 Bodily pain 80 [47-100] 
 general health 50 [40-70] 
 Physical health summary 74 [52-88] 
 mental health summary 69 [45-82] 
Country of origin
 Asia 29% 
 Netherlands 24% 
 turkey / Northern Africa 17% 
 surinam 12% 
 sub-saharan Africa 6% 
 other 12% 
marital status
 married / in a relationship 54% 
 single 29% 
 Divorced / widowed / unknown 17% 
employment status
 Paid employment 52% 
 Disabled 15% 
 retired 12% 
 other 21% 
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DNA levels, 15 patients (15%) exhibited positive but unquantifiable HBV DNA (<20 IU/mL) 
and in 18 patients (18%) HBV DNA levels >20 IU/mL were measured. Of those, 11 patients 
had an HBV DNA level between 20 and 200 IU/mL, whereas in 7 patients HBV DNA levels 
above 200 IU/mL were observed. In none of the patients a virologic breakthrough was 
observed. When comparing the 81 patients with either undetectable or unquantifiable 
HBV DNA with the 18 patients with HBV loads >20 IU/mL, some differences in patient 
characteristics and adherence were observed. (Table 5) Patients with high viral loads were 
significantly younger, were less frequently treated with other NA before start of ETV and 
duration of ETV treatment was shorter compared to patients with HBV DNA loads <20 IU/
table 4. Predictors of ≥80% (good) adherence in 100 CHB patients on entecavir treatment
Adherence ≥80%
(n=70)
Adherence <80%
(n=30)
P-value
male gender 73% 83% 0.26
Age, years 47±13 40±15 0.01
marital status: married 56% 52% 0.72
Country of origin: 27%-26%-47% 33%-20%-47% 0.75
 Asia vs. NL vs. other 
sf-36: physical health* 69 ± 24 68 ± 27 0.88
sf-36: mental health* 64 ± 23 62 ± 25 0.82
BmQ specific: attitude 0.03
 Accepting 42% 18% 
 Ambivalent 56% 64% 
 Indifferent 2% 18% 
BmQ general: Harm# 56% 53% 0.81
BmQ general: overuse# 77% 82% 0.65
BmI, kg/m2 25.4±4.5 25.4±4.0 0.95
Presence of cirrhosis 29% 30% 0.76
HBe negativity 67% 60% 0.52
Psychiatric comorbidity 16% 20% 0.60
Any comorbidity 57% 47% 0.34
≥ 1 other medication 51% 37% 0.18
History of Peg-IfN 29% 30% 0.89
History of other NuC 29% 23% 0.58
entecavir ≥ 1 year 70% 60% 0.33
HBv DNA ever undetectable 79% 78% 0.97
Alcohol >5units/wk, present 11% 10% 0.83
Alcohol >5units/wk, past 19% 23% 0.59
*also no significant differences in the separate SF-36 scales (data not shown)
# percentage of patients with average score >2,5 on the subscale, also no significant differences in mean 
scores (data not shown)
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mL. Furthermore, the vast majority of patients with high viral loads was HBeAg positive 
and exhibited HBV DNA > 20 IU/mL at inclusion in the study. Adherence tended to be 
lower among patients with high viral loads: 83% vs. 91% (p=0.19). However, after adjust-
ment in multivariate analysis for duration of ETV treatment (adjusted OR 18.8 (4.1-87.0, 
p<0.001) and HBeAg status (adjusted OR 11.9 (2.6-53.6), P=0.001), adherence was not a 
significant predictor of HBV treatment response (adjusted OR 1.02 (0.98-1.07), p=0.34).
We also compared adherence rates between patients with HBV loads 20-200 and >200 
IU/mL to evaluate if more pronounced differences in adherence could be found between 
these subgroups. Duration of ETV treatment (3 [2-18] vs. 2 [0-7] months, p=0.10), age 
(38 vs. 30 years, p=0.13) and also adherence (95% vs. 71%, p=0.10) tended to be less in 
patients with HBV DNA >200 IU/mL, whereas no differences in HBeAg status and pres-
ence of cirrhosis were observed. Given the small number of patients in these subgroups 
multivariate analysis was not performed.
table 5. Covariates associated with virological response (univariate analysis) in 100 CHB patients on ente-
cavir treatment
HBv DNA
<20 Iu/mL
(n=81)
HBv DNA
>20 Iu/mL
(n=18)
or (95% CI) P-value
male gender 62 (77%) 13 (72%) 1.26 (0.40-3.97) 0.70
Age, years 47 [39-56] 32 [27-45] 1.06 (1.01-1.11) 0.001
marital status: married 46 (58%) 8 (44%) 1.69 (0.60-4.74) 0.32
Presence of cirrhosis 22 (27%) 6 (33%) 0.63 (0.20-1.95) 0.42
HBe negativity 58 (72%) 5 (28%) 6.05 (0.92-19.12) 0.002
Any comorbidity 44 (54%) 9 (50%) 1.19 (0.43-3.31) 0.74
≥ 1 other medication 38 (47%) 8 (44%) 1.11 (0.40-3.09) 0.85
History of Peg-IfN 25 (31%) 4 (22%) 1.56 (0.47-5.22) 0.47
History of other NuC 25 (31%) 2 (11%) 3.57 (0.76-16.72) 0.11
entecavir tx, months 29 [13-54] 3 [2-13] 1.08 (1.03-1.14) 0.002
entecavir ≥ 1 year 61 (75%) 5 (28%) 7.93 (2.52-25.01) <0.001
Alcohol, past 10 (12%) 4 (22%) 0.86 (0.25-2.97) 0.81
HBv DNA at incl <20 Iu 73 (91%) 2 (11%) 83,4 (15.8-439.7) <0.001
Adherence, % 91 [75-99] 83 [60-97] 1.02 (0.99-1.05) 0.19
Adherence ≥80% 58 (72%) 11 (61%) 1.61 (0.55-4.65) 0.38
Adherence ≥90% 44 (54%) 7 (39%) 1.87 (0.66-5.31) 0.24
max interval between doses 3 [2-4] 4 [2-11] 0.99 (0.94-1.04) 0.62
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DIsCussIoN
In this study we assessed adherence to ETV treatment in 100 consecutive CHB patients 
using real-time medication monitoring. Our main findings are that adherence averaged 
85% during 16 weeks and that even in case of poor adherence, virologic response often 
appeared to be sufficient.
Our results on adherence are comparable with the few previous studies that assessed 
adherence in CHB patients. In a recent systematic review we concluded that mean ad-
herence to NA therapy in CHB patients ranged from 81% to 99%, with 66% to 92% of pa-
tients being 100% adherent.25 Adherence in those studies was measured by self-report, 
pharmacy refill data or pill count. Of special interest is the study by Chotiyaputta et al.26, 
who - based on pharmacy claims of 11.100 patients - reported an adherence rate of 88% 
for various NA. Of the 2434 patients on ETV, 59% exhibited >90% adherence, compared 
to 52% in our study. Poor adherence seems to occur less frequently in CHB patients than 
in patients with other chronic (asymptomatic) diseases. For example, adherence rates 
after 6 months and 3 year of statins for secondary prevention of cardiovascular disease 
were 71% and 45%, respectively, while for primary prevention this was 65% and 35%, 
respectively.12 Similar results were obtained for antihypertensive medication.11
In our study, poor adherence was associated with younger age, which is in line with 
previous research.26-28 No other demographic or treatment-related predictors of non-
adherence could be identified. However, patients’ attitude towards medication appeared 
to be significantly associated with adherence, with patients with an “indifferent” attitude 
(low necessity as well as low concerns score) being more prone to poor adherence and 
patients with an “accepting” attitude (high necessity score, low concerns score) being 
more prone to good adherence. We are the first to assess CHB patients’ beliefs about 
medicine using the BMQ-questionnaire. In other chronic diseases it has been shown that 
attitude towards medication is an important predictor of non-adherence.21-24
We also assessed potential consequences of poor adherence for virologic response. The 
frequency of virologic breakthrough during ETV therapy has previously been estimated 
at 1-3% during 3-5 years of follow-up.7,8 However, virologic breakthrough did not occur 
in our study, which is possibly related to the relatively low number of included patients 
and the relatively short follow-up. Also, we did not measure HBV DNA levels at the 
end of the interruption periods (up to 53 days interruption). Adherence tended to be 
lower among the 18% of patients that exhibited HBV DNA >20 IU/mL after 16 weeks of 
treatment in our study, compared to patients with undetectable HBV DNA. However, 
after adjustment for duration of ETV treatment and HBeAg status, adherence was not 
found to be a significant predictor of HBV treatment response. This finding suggests 
that virologic response can often be maintained even in case of poor adherence. Previ-
ous studies have reported a significant association between adherence and virologic 
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response.27-30 However, none of these previous studies focused exclusively on ETV which 
is a potent NA with a high barrier to resistance, at least in treatment-naive patients.
Our study has several strengths and some limitations. We are the first to provide pro-
spectively collected adherence data in CHB patients using the Sensemedic medication 
dispenser, which is the most reliable method to measure adherence. Furthermore, our 
patient cohort is representative for the total cohort of CHB patients on NA treatment, 
since we did not exclude patients based on, for example, previous NA treatment or 
co-morbidities. A possible limitation of our study could be that adherence rates may 
have been influenced by participation in a study. In our opinion, it seems unlikely that 
participation in the study would have affected adherence results during the entire 16 
weeks. It would be very interesting to correlate plasma levels with electronic adherence 
data. Unfortunately, measurement of ETV plasma levels is currently not possible. Last, 
one could hypothesize that opening of the medication dispenser is no guarantee for 
medication intake by the patient. Also, absence of a signal indicating opening of the 
dispenser does not have to indicate non-adherence. However, it has been shown that 
mismatches between electronic detection of opening of the medication dispenser and 
actual dosing are rare.31,32
In conclusion, 70% of our CHB patients exhibited good adherence to ETV therapy, with 
younger patients and those with an indifferent attitude being more prone to poor ad-
herence. Adherence and patient attitude were not independent predictors of virologic 
response.
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Chronic hepatitis B (CHB) remains one of the most prevalent infectious diseases.1 Infec-
tion with the hepatitis B virus (HBV) can lead to acute hepatitis which can either resolve 
spontaneously, become chronic or result into a fulminant hepatitis with liver failure.2,3 
Patients with CHB may present in any of four phases of infection, depending on the 
presence of hepatitis B e antigen (HBeAg) with/without its antibody anti-HBe and serum 
levels of HBV DNA and alanine aminotransferase (ALT).3
To prevent progression to cirrhosis, liver failure, hepatocellular carcinoma and liver-
related death many CHB patients require antiviral therapy. The potential of antiviral 
therapy for CHB increased enormously over the last years as a result of the introduction 
of better nucleos(t)ide analogues (NA) and of a pegylated form of interferon-α (PEG-IFN).
PreDICtINg resPoNse to PegINterferoN tHerAPy
Since an off-treatment sustained response can be achieved in a considerable number 
of patients after a finite treatment course, PEG-IFN remains an important first-line treat-
ment option for CHB.4-8 Response to (PEG-)IFN-based therapy is accompanied by increas-
ing rates of hepatitis B surface antigen (HBsAg) seroconversion, a reduced incidence of 
hepatocellular carcinoma and prolonged survival.7,9-11
It has previously been shown that serum HBsAg levels at baseline and during PEG-IFN 
treatment can predict response.12-14 However, there is a lack of knowledge regarding 
the effect of PEG-IFN on the expression of intrahepatic hepatitis B core antigen (HBcAg) 
and HBsAg in CHB. In Chapter 1 we showed in a group of 119 CHB patients with paired 
biopsies taken at baseline and after one year of PEG-IFN therapy that PEG-IFN reduces 
the expression of intrahepatic HBsAg. More importantly, loss of HBsAg as assessed by 
immunohistochemistry from the liver predicted sustained response, and was reflected 
in a pronounced serum HBsAg decline. These results provide an important rationale 
for the use of HBsAg quantification as an easily obtainable estimate for prediction of 
response to PEG-IFN in both HBeAg positive and negative CHB.
Yet, since treatment with PEG-IFN is often accompanied by the occurrence of side-effects 
such as flu-like symptoms, headache, myalgia, fatigue and local reactions at the site of 
injection, the clinical use of PEG-IFN is compromised.15 Selection of patients with the 
highest probability of achieving a response to PEG-IFN is therefore essential to success-
ful application of this agent. Several factors have been related to a favorable response 
to PEG-IFN therapy in CHB, such as HBV genotype A and B, low baseline HBV DNA, high 
baseline ALT, older age, female sex, no previous IFN therapy and absence of precore 
(PC) and basal core promotor (BCP )mutants.16-18 Nevertheless, discrimination remains 
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limited and identification of other baseline or on-treatment factors that influence the 
probability of response is required in order to develop a better prediction model.
In Chapter 2, we therefore investigated whether presence of anti-interferon antibodies 
affects the probability of response to PEG-IFN in CHB patients. The occurrence of anti-
IFN antibodies has been associated with non-response to PEG-IFN in chronic hepatitis 
C.19,20 We showed in this study of 323 CHB patients treated with PEG-IFN that presence of 
anti-IFN antibodies was associated with previous IFN therapy failure. However, presence 
or development of anti-IFN antibodies during or after PEG-IFN therapy was not associ-
ated with non-response to PEG-IFN treatment in CHB. Thus, there appears to be no role 
for measurement of anti-IFN antibodies in predicting response to PEG-IFN in CHB.
It has been shown that both viral as well as host factors influence response to PEG-
IFN therapy.16-18 We therefore hypothesized that the most optimal response to PEG-IFN 
therapy can be expected in the presence of both a susceptible host and a susceptible 
virus. In Chapter 3 we showed that high levels of interferon gamma inducible protein 
(IP)-10 predict HBeAg loss and that a combination of high serum levels of ALT or IP-10 
(both markers of an active immune response), together with absence of PC and BCP 
mutants identified patients with a very high likelihood of response to PEG-IFN therapy.
Combined use of the described predictors of response to PEG-IFN may help select 
patients with the most favourable characteristics for PEG-IFN therapy. This will possibly 
result in a more attractive cost-benefit ratio for this treatment option in the future.
NuCLeos(t)IDe ANALogue tHerAPy AND CLINICAL outCome
With the introduction of NA in the early nineties, the landscape of treatment for CHB 
has undergone great changes. Large cohort studies with untreated patients have shown 
that HBV DNA levels are associated with risk of liver disease progression and HCC devel-
opment.21,22 Therefore, antiviral treatment with NA aims at competitively inhibiting viral 
polymerase activity.23 As the most recently approved NA Entecavir (ETV) and Tenofovir 
(TDF) can effectively maintain suppression of HBV DNA levels for prolonged periods of 
time in the vast majority of patients 24-28, these are recommended as first-line treatment 
in current guidelines. Recently, it has also been shown that ETV and TDF may improve 
fibrosis scores after continuous therapy and reduce the risk of HCC and liver related 
events, particularly in patients with cirrhosis.27,29-32
In order to predict the risk of HCC in treatment-naïve patients, HCC risk scores have been 
developed. Recently, these HCC risk scores were shown to predict HCC in Asian CHB 
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patients treated with ETV as well.33 However, the performance of these risk-scores in 
non-Asian patients is unknown. In Chapter 4 we studied in a large ethnically diverse 
European HBV infected population treated with ETV the incidence of, and risk factors 
for development of liver-related events including HCC, and the role of risk-scores for 
prediction of HCC. In our cohort of 744 CHB patients treated with ETV we showed that 
continuous ETV therapy effectively suppressed HBV DNA in the vast majority of patients. 
However, while the risk of HCC in ETV treated patients was low through up to five years 
of treatment, ETV therapy did not eliminate the risk of HCC. Furthermore, the previously 
described risk-scores for HCC appeared not to be clinically useful either at baseline nor 
during therapy, particularly in Caucasians. Despite successful ETV therapy, we therefore 
recommend to continue screening of risk groups.
ETV is a cyclopentyl guanosine analogue and it has shown superior biochemical, viro-
logical and histological efficacy and HCC-free survival compared to first generation NA, 
such as lamivudine (LAM).34,35 Moreover, genotypic resistance to ETV is rare through five 
years of continuous therapy and ETV resistance in LAM-naïve patients has only been 
described in few reports.36-38 Avoiding viral resistance is a cornerstone of CHB treatment 
as resistance is associated with a worsened outcome.39 After achieving an undetectable 
HBV DNA the risk of developing resistance to potent ETV and TDF is thought to be 
minimal.
Current guidelines recommend long-term continuation of NA treatment, unless there 
is genotypic resistance or HBeAg or preferably HBsAg seroconversion.40,41 Therefore, 
therapy is rarely stopped. However, it is unclear whether treatment adaptation is neces-
sary for patients who develop a flare during NA treatment. Flares during IFN treatment 
can be severe, but have also been associated with virologic response.42 Flares during 
NA therapy are rare and are mostly associated with antiviral resistance or cessation of 
therapy.43,44 In Chapter 5, we showed that only 19 of 733 patients (3%) experienced a 
flare during ETV therapy. More interestingly, flares occurring before week 26 of therapy 
and in patients without cirrhosis were almost exclusively present during continued de-
cline of HBV DNA. We therefore recommend to continue ETV therapy in these patients as 
the majority had a good biochemical and virologic outcome. Interestingly, none of the 
patients with a flare developed antiviral resistance.
Non-compliance has also been proposed as a possible factor of non-response and de-
velopment of antiviral resistance or flares during ETV therapy.45,46 Therefore, in Chapter 
6 we investigated data on adherence to NA in CHB patients using real-life prospective 
data including real-time medication monitoring (RTMM) during 16 weeks of follow-up. 
We showed in a group of 100 CHB patients treated with ETV that 70% of CHB patients 
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exhibited good adherence (>80%) to ETV therapy, with younger patients and those with 
an indifferent attitude (according to the “beliefs about medicines” questionnaire (BMQ)) 
being more prone to poor adherence (<80%). Interestingly, adherence and patient at-
titude were not independent predictors of virologic response. No viral break-through 
occurred during the study period.
It has previously been shown that stopping NA results in a relapse of HBV infection in the 
majority of patients.47 It must therefore be outlined that NA should most likely be given 
indefinitely to the vast majority of patients. Thus, long-term side effects and costs of NA 
should also be taken into account when initiating such therapy.
CoNCLusIoNs
For CHB patients who require treatment both PEG-IFN and NA are still considered first 
line treatment. PEG-IFN should only be given in patients with the highest probability 
of response. For prediction of response to PEG-IFN in CHB patients serum HBsAg levels 
can be used as an easily obtainable estimate. Furthermore, high ALT and high IP-10 - 
indicators of a susceptible host - are associated with a higher probability of response 
to PEG-IFN. However, measurement of anti-IFN antibodies before or during PEG-IFN 
therapy does not predict response and is therefore not recommended. Treatment with 
ETV results in undetectable HBV DNA in most patients and is associated with a low risk 
of development of HCC or a flare. However, known risk-scores for HCC are not clinically 
useful either at baseline nor during therapy, particularly in Caucasians. Moreover, as pa-
tients remain at risk to develop HCC or ALT flares, we recommend to continue intensive 
follow-up. Finally, it must be anticipated that NA should be given indefinitely in the great 
majority of patients. Thus, long-term side effects and costs of NA should also be taken 
into account when initiating such therapy.
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Chronische infectie met het Hepatitis-B-virus (HBV) blijft, ondanks de introductie van 
veilige en effectieve vaccins ongeveer twee decennia geleden, een veelvoorkomend 
probleem. De wereldwijde incidentie wordt geschat op zo’n 350 miljoen patiënten en 
zelfs een derde van de wereldbevolking heeft ooit een infectie met HBV doorgemaakt.1
Infectie met het HBV kan leiden tot een acute hepatitis. Deze kan vervolgens spontaan 
genezen, of kan resulteren in een chronische vorm of een ernstige fulminante hepatitis 
met leverfalen als gevolg.2,3
Om progressie naar cirrose, leverfalen, hepatocellulair carcinoom (HCC) en lever-gere-
lateerde sterfte te voorkómen, heeft een groot deel van de chronische hepatitis B (CHB) 
patiënten antivirale behandeling nodig. De laatste jaren is er veel bekend geworden over 
het natuurlijk beloop van de ziekte, alsook de nieuwe therapeutische mogelijkheden.
Behandeling van CHB is geïndiceerd wanneer er sprake is van actieve replicatie van het 
HBV (serum HBV-DNA>2,0 X 10E4 IU/ml) met daarbij activiteit van leverziekte, weerge-
geven door de hoogte van het serum ALAT en/of de ernst van necro-inflammatie in het 
leverbiopt.4-6
Doel van behandeling is de kwaliteit van leven te verbeteren en de kans op overleven van 
patiënten met CHB te vergroten door het voorkómen van progressie van ziekte. Daarbij 
is het verlies van hepatitis B surface antigen (HBsAg) en de vorming van de betrokken 
antistof anti-HBs het ultieme doel. Aangezien dit echter slechts in enkele gevallen wordt 
bereikt, zijn surrogaat eindpunten gedefinieerd, zoals virologische respons (HBV DNA on-
derdrukking), biochemische respons (ALAT normalisatie), serologische respons (HBeAg-
verlies en –seroconversie) en histologische respons (histologische verbetering).4
HuIDIge tHerAPIeëN
Momenteel zijn er zeven middelen geregistreerd voor de behandeling van CHB. Ener-
zijds zijn er de immuun-modulerende interferonen en anderzijds de direct anti-virale 
nucleoside analogen (NA’s), die weer in drie klasse onderverdeeld kunnen worden, te 
weten L-nucleosides (Lamivudine, Telbivudine), deoxyguanosine analogen (Entecavir) 
en acyclische nucleoside fosfonaten (Adefovir en Tenofovir).
voorspellen van respons op Peginterferon therapie
Het (secundaire) antivirale effect van de immuunmodulerende interferonen werd 
voor het eerst beschreven in 1957 en sinds de jaren ‘80 wordt Interferon-alfa toege-
past voor de behandeling van CHB. Sinds een aantal jaren is door het binden van een 
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polyethyleenglycol(PEG)-molecuul aan interferon (PEG-IFN) de effectiviteit van behande-
ling toegenomen. PEG-IFN wordt wekelijks toegediend door middel van een subcutane 
injectie, wat resulteert in een redelijk gelijkmatige IFN spiegel gedurende dit interval.
Zowel voor HBeAg-positieve als HBeAg-negatieve patiënten blijft PEG-IFN een eer-
stelijns behandeloptie aangezien het bij ongeveer 30% van de patiënten resulteert in 
blijvende respons na één jaar behandeling.7-11 Daarnaast is respons op PEG-IFN therapie 
geassocieerd met toenemende kansen op HBsAg seroconversie, een lager risico op HCC 
en langere overleving.10,12-14
Het is recent aangetoond dat de hoeveelheid serum HBsAg voor het starten van en 
tijdens PEG-IFN behandeling voorspellers zijn van respons.15-17
Het effect van PEG-IFN op de expressie van intrahepatisch hepatitis B core antigen (HB-
cAg) en HBsAg is echter niet bekend. In een groep van 119 CHB patiënten met gepaarde 
biopten toonden wij in Hoofdstuk 1 aan dat na een jaar behandeling met PEG-IFN de 
expressie van intrahepatisch HBsAg verlaagt. Daarnaast bleek het dat verlies van intra-
hepatisch HBsAg, gemeten met behulp van immunohistochemie, een voorspeller was 
van blijvende respons, en werd gereflecteerd in een daling van het HBsAg in het serum. 
Een eenvoudig uit te voeren serum HBsAg bepaling lijkt dan ook correct gebruikt te 
kunnen worden als voorspeller van respons op PEG-IFN in zowel HBeAg positieve als 
negatieve CHB patiënten.
Het klinisch gebruik van PEG-IFN wordt echter bemoeilijkt door de vaak optredende 
bijwerkingen, zoals griepachtige verschijnselen, lokale reacties op de injectieplaats, 
beenmergsuppressie en psychische problematiek.18 Selectie van patiënten met de 
hoogste kans op respons is daarom essentieel voor succesvol gebruik van PEG-IFN.
Verschillende factoren zijn de afgelopen jaren naar voren gekomen als mogelijke voor-
spellers van respons. Het is gebleken dat een lage virale load, een hoog serum ALAT, 
infectie met HBV genotype A of B, een hogere leeftijd, vrouwelijk geslacht, niet eerder 
behandeld zijn met IFN en afwezigheid van precore (PC) en core promotor (BCP) mutanten 
de kans op succes van behandeling vergroten.19,20 Helaas is echter de betrouwbaarheid 
van voorspelling op individueel niveau beperkt en rest er een grote onzekerheid welke 
patiënt succesvol met PEG-IFN behandeld kan worden. Identificatie van extra factoren 
die respons kunnen voorspellen is daarom van essentieel belang.
In Hoofdstuk 2 onderzochten wij of de aanwezigheid van anti-interferon (anti-IFN) 
antilichamen invloed had op de responskansen op PEG-IFN in CHB patiënten. De aan-
wezigheid van anti-IFN antilichamen is in de behandeling van chronische hepatitis C 
met PEG-IFN geassocieerd met non-response.21,22 In een groep van 323 CHB patiënten, 
die behandeld werden met PEG-IFN, hebben we aangetoond dat de aanwezigheid van 
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anti-IFN antilichamen geassocieerd was met eerder falen van (PEG-)IFN behandeling. De 
aanwezigheid of ontwikkeling van anti-IFN antilichamen tijdens of na PEG-IFN behande-
ling was echter niet geassocieerd met non-response op PEG-IFN behandeling in CHB 
patiënten. Het bepalen van anti-IFN antilichamen om respons kans op PEG-IFN in CHB 
patiënten te voorspellen lijkt dan ook niet zinvol.
Eerder onderzoek van onze groep toonde aan dat de aanwezigheid van PC en BCP mutan-
ten invloed heeft op een blijvend hoog serum HBV DNA na HBeAg verlies. Het lijkt er dan 
ook op dat succesvolle behandeling met PEG-IFN afhangt van zowel de gevoeligheid van 
de drager alsook de gevoeligheid van het virus.19,20,23 In Hoofdstuk 3 toonden wij aan dat 
hoge waarden van interferon gamma inducible protein-10 (IP-10) HBeAg verlies voorspel-
den en dat een combinatie van een hoog ALAT of IP-10 (beide markers van een actieve 
immuun response), samen met de afwezigheid van PC- en BCP-mutanten kan helpen in 
het identificeren van patiënten met een grote kans op respons op PEG-IFN behandeling.
Het combineren van de beschreven voorspellers van respons op PEG-IFN kan derhalve 
helpen alleen die patiënten te selecteren met de meest gunstige karakteristieken voor 
PEG-IFN therapie en dus een hoge kans op succes van therapie. Dit zal mogelijk ook 
resulteren in een betere kosten-baten ratio voor PEG-IFN behandeling in de toekomst.
Nucleoside analogen en lange termijn respons
De laatste decennia is met de introductie van NA’s grote vooruitgang geboekt in de 
behandeling van CHB. Door de directe onderdrukking van de virale replicatie - door 
remming van het virale polymerase - leidt behandeling met NA’s bij vrijwel alle patiën-
ten na één jaar tot een daling van HBV DNA en ALAT en in stijgende mate daarnaast tot 
verbetering van de leverhistologie. NA’s moeten dagelijks oraal worden ingenomen en 
hebben weinig bijwerkingen.
Grote cohort studies met onbehandelde Aziatische patiënten hebben laten zien dat HBV 
DNA levels geassocieerd zijn met het risico op progressie van leverziekte en de ontwik-
keling van HCC.24,25 Complete onderdrukking van virale replicatie naar ondetecteerbare 
HBV DNA waarden wordt momenteel dan ook beschouwd als één van de belangrijkste 
surrogaat eindpunten van NA therapie.26 De meest recent goedgekeurde NA’s Entecavir 
(ETV) en Tenofovir (TDF) worden in de huidige richtlijnen geadviseerd als eerstelijns mo-
notherapie vanwege hun potentie (snelheid van onderdrukking van virale replicatie), de 
hoge genetische barrière tegen resistentie en de beperkte bijwerkingen.27,28 Zowel ETV 
als TDF therapie kunnen langdurige onderdrukking van HBV DNA levels bewerkstelligen 
in vrijwel alle CHB patiënten.28-33 Het is daarnaast recent aangetoond dat continue ETV 
en TDF therapie leverfibrose kunnen verminderen alsook het risico op HCC en lever-
gerelateerde sterfte kunnen reduceren, met name in patiënten met cirrose.31,34-37
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Om het risico op HCC te voorspellen in onbehandelde patiënten zijn er HCC risico scores 
ontwikkeld, welke recent hebben laten zien ook het risico op HCC in Aziatische CHB 
patiënten die behandeld worden met ETV te kunnen voorspellen. 38 Het is echter niet 
bekend of deze HCC risico scores ook geschikt zijn in niet-Aziatische patiënten.
In Hoofdstuk 4 onderzochten wij de incidentie van, en de risicofactoren voor het ont-
wikkelen van lever-gerelateerde events inclusief HCC en de rol van HCC risico-scores in 
het voorspellen van HCC in een groot Europees cohort van CHB patiënten. In ons cohort 
van 744 CHB patiënten, die behandeld werden met ETV toonden we aan dat continue 
ETV therapie HBV DNA onderdrukt in vrijwel alle patiënten. Daarnaast bleek dat het 
risico op HCC in ETV behandelde patiënten laag was (1.9%). Behandeling met ETV kon 
echter niet het risico op HCC volledig doen verdwijnen. Daarnaast bleek dat de eerder 
beschreven risico-scores voor HCC niet klinisch bruikbaar waren aan het begin of gedu-
rende de behandeling met ETV, met name niet in de Kaukasische populatie. Het wordt 
dan ook aangeraden om ook patiënten met succesvolle ETV behandeling frequent te 
blijven vervolgen en HCC screening te continueren, met name in risicogroepen.
ETV is een cyclopentyl guanosine analoog welke superieure biochemische, virologische 
en histologische effectiviteit en HCC-vrije overleving heeft laten zien in vergelijking met 
eerste generatie NA’s, zoals lamivudine (LAM).39,40 Daarnaast is gebleken dat antivirale 
resistentie gedurende ETV zeer zeldzaam is, tot vijf jaar na het starten van de behande-
ling.41-43 Het voorkómen van antivirale resistentie is een belangrijk onderdeel van de 
behandeling van CHB patiënten, aangezien antivirale resistentie geassocieerd is met 
een slechtere uitkomst.44
Huidige richtlijnen adviseren NA’s langdurig en misschien wel levenslang te continueren, 
en alleen te wijzigen als er sprake is van antivirale resistentie of te staken in geval van 
HBsAg seroconversie.4,5 Aangezien dit zeer sporadisch voorkomt, wordt behandeling 
met NA’s vrijwel nooit gestaakt. Het is echter onbekend of verandering van behandel-
ing ook nodig is bij patiënten die een flare (stijging van het serum ALAT tot boven drie 
keer de normaal waarde) ontwikkelen tijdens behandeling met NA’s. Het is bekend 
dat tijdens behandeling met IFN ernstige flares kunnen ontstaan. Deze kunnen echter 
ook geassocieerd zijn met virologische en/of serologische respons.45 Flares tijdens NA 
behandeling zijn zeldzaam en meestal geassocieerd met antivirale resistentie of staken 
van therapie.46,47
In Hoofdstuk 5, lieten we zien dat slechts 19 van de 733 patiënten (3%) een flare ontwik-
kelden tijdens behandeling met ETV. Daarnaast bleek dat flares die ontstonden in het 
eerste half jaar van therapie en in patiënten zonder cirrose vrijwel altijd geassocieerd 
waren met een persisterende daling van het serum HBV DNA. Het valt daarom aan te 
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bevelen om ETV behandeling te continueren in deze groep patiënten, omdat de meer-
derheid een goede biochemische en virologische uitkomst had. Daarnaast ontwikkelde 
geen van deze patiënten antivirale resistentie.
Therapieontrouw wordt als een mogelijke oorzaak van non-response en het ontwik-
kelen van antivirale resistentie of flares tijdens ETV therapie beschouwd. In Hoofdstuk 
6 beschreven wij het effect van ETV therapietrouw in een groep van 100 CHB patiënten 
die behandeld worden met ETV. Hiervoor maakten wij gebruik van een speciaal me-
dicijndoosje dat medicijngebruik real-time registreert. Wij toonden daarbij aan dat 
tijdens de studieperiode van 16 weken 70% van de CHB patiënten therapietrouw was 
(gedefinieerd als ≥80% therapietrouw). Daarnaast bleek dat CHB patiënten met slech-
tere therapietrouw (<80%) jongere patiënten waren en vaker een negatieve attitude ten 
opzichte van ETV hadden (gebaseerd op de BMQ-vragenlijst, een gevalideerde vragen-
lijst op het gebied van medicatiegebruik). Geen enkele patiënt kreeg een virologische 
doorbraak tijdens de studieperiode. Therapietrouw en patiëntenattitude waren echter 
geen onafhankelijke voorspellers voor virologische respons. Het wordt wel aanbevolen 
om tijdens behandeling met NA’s patiënten initieel frequent te vervolgen (eenmaal per 
drie maanden) om de therapietrouw te monitoren en eventuele antivirale resistentie 
tijdig te detecteren om zodoende een biochemische doorbraak te voorkómen.
Conclusies
Met de beschikbaarheid van nieuwe antivirale middelen is het momenteel voor vrijwel 
alle CHB patiënten haalbaar HBV medicamenteus onder controle te houden door het 
induceren van een blijvende respons met PEG-IFN, of het onderhouden van een respons 
door middel van langdurige NA therapie.
Behandeling met PEG-IFN moet alleen gegeven worden aan die patiënten met een hoge 
kans op respons op PEG-IFN. Om respons op PEG-IFN te voorspellen kunnen serum HB-
sAg levels gebruikt worden. Daarnaast is gebleken dat een hoge IP-10 waarde – als mar-
ker voor gevoegheid van de drager - geassocieerd is met een grotere kans op respons.
De aanwezigheid of het ontwikkelen van anti-interferon antilichamen heeft echter geen 
invloed op respons op PEG-IFN en het wordt dan ook niet aangeraden deze te bepalen.
Ten aanzien van NA behandeling is gebleken dat ETV therapie in vrijwel alle patienten 
resulteert in een ondetecteerbaar HBV-DNA en daarnaast geassocieerd is met een laag 
risico op het ontwikkelen van een HCC of een flare. Bekende HCC risicoscores bleken 
echter klinisch niet bruikbaar voor het voorspellen van HCC voor of tijdens ETV behan-
deling, met name niet in Kaukasische patiënten. Langdurige follow-up blijft dan ook van 
belang, ondanks goede respons op ETV.
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“Ne marche pas devant moi, je ne suivrais pas. Ne marche pas derrière moi, je ne dirigerais 
pas. Marche simplement prés de moi, et sois mon ami.” Albert Camus.
Onder het motto “je kan er niet vroeg genoeg mee beginnen” heb ik ruim drie jaar 
geleden, tijdens een moment van bezinning op de beruchte dakpoli, al eens een begin 
gemaakt aan dit dankwoord. Helaas is het destijds bij een opzetje gebleven en moet ik 
het nu alsnog - net als veel van mijn stukken de afgelopen jaren - achtervolgd door een 
strakke deadline in een van mijn nachtdiensten afronden.
Tijdens mijn promotietijd heb ik veel leerzame, mooie en gezellige momenten beleefd 
waar ik iedereen graag voor wil danken. Een aantal mensen wil ik hier graag in het 
bijzonder bedanken. 
Allereerst wil ik mijn promotor professor H.L.A. Janssen bedanken. Beste Harry, onder jouw 
leiding heeft het HBV onderzoek in Nederland een plaats verworven in de wereldtop. Ik wil 
je bedanken voor de vele mogelijkheden die je mij hebt geboden. De klinische en weten-
schappelijke ervaring die ik de afgelopen jaren heb opgedaan zal ik mijn verdere carrière 
meedragen. Je bent een zeer gedreven wetenschapper en laat geen kans onbenut. Dit 
verwacht je ook van je promovendi wat naast enige stressmomenten vaak resulteert in 
goede resultaten. Dat je naar Canada vertrok, was even wennen, maar ondanks de afstand 
is de samenwerking altijd prima verlopen en ik geloof dat je daar nu helemaal op je plek 
zit. Ik wens je in elk geval alle succes en geluk in Toronto.
Daarnaast natuurlijk mijn copromoter dr. B.E. Hansen. Beste Bettina, je was mijn 
statistische steun en toeverlaat. De brainstormsessies bij jou thuis waren altijd perfect 
geregeld, goed productief, maar vooral ook erg gezellig. Bedankt voor al je hulp de 
afgelopen jaren.
Ook wil ik de overige commissieleden hartelijk danken voor het beoordelen van mijn 
manuscript en plaatsnemen in de commissie.
Mijn huidige opleider dr. R.A. de Vries. Beste Richard, bedankt voor het in mij gestelde 
vertrouwen. Ik heb het erg naar mijn zin in Amsterdam en kijk er naar uit te starten met 
de MDL-vervolgopleiding.
Dear (international) co-authors of the various manuscripts, thank you very much for the 
collaboration, your valuable input and your warm welcomes during my visits across Europe.
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Ook wil ik alle patiënten die hebben deelgenomen aan de wetenschappelijke studies 
graag bedanken. Zonder hen en hun families waren veel studies niet mogelijk geweest.
Hepatitis B onderzoek doe je in het Erasmus MC niet alleen. Milan, jij bent het statistisch 
wonder van de afdeling en altijd bereid je kennis met anderen te delen. Roeland, jij hebt 
mij geïntroduceerd in de wereld van de hepatitis B poli’s en later heb ik ook nog eens 
jouw studie overgenomen. Ik wil jullie beiden heel erg bedanken voor al jullie hulp, pep-
talks en gezelligheid de afgelopen jaren, op het dak, maar ook  tijdens borrels, etentjes 
en congressen. WP, jij nam als laatst het stokje van Roeland over en samen regelden wij 
de vele Hepatitis B (studie)poli’s, die vaak genoeg gespreksstof opleverden voor tijdens 
de vele Starbucksjes. Bedankt voor al je hulp en gezelligheid en veel succes met het 
afronden van je promotie. Ook wil ik mijn voorgangers Vincent en Jurrien bedanken 
voor het werk dat al gedaan was alsook voor hun hulp daarna bij de voltooiing van mijn 
onderzoek. Heng en Margot, ik kijk erg uit naar de eerste resultaten van de PEGON en 
de PAS-studie en wens jullie heel veel succes met het afronden van jullie promoties. 
Dr. Rob de Knegt, na Harry’s vertrek nam jij de HBV-taken op je. Dank voor de gezellige 
poli-besprekingen, inclusief de laatste (maatschappelijke) nieuwtjes.
Daarnaast wil ik iedereen van het MDL-onderzoeksbureau heel erg bedanken. Irene, 
Elke en Judith en research nurses,  Heleen, Lucille en Melek  voor jullie een speciaal 
woord van dank. Al jullie hulp rondom de logistieke zaken van de verschillende (inter)
nationale studies was onmisbaar. Ook de polidames en poliheer en in het bijzonder 
Wilma, bedankt voor alle hulp tijdens mijn soms overvolle HepB2 poli’s.
Alle collega’s op het MDL-lab wil ook hartelijk danken. In het bijzonder Andre, Hanneke, 
Anthony en Gertine heel erg bedankt voor al jullie hulp bij de vele bepalingen. Zonder 
virologische data en input van de afdeling Virologie zou dit proefschrift niet tot stand 
zijn gekomen. Annemiek, Suzan, Bart en Sandra, dank voor de prettige samenwerking 
op de diverse projecten de afgelopen jaren. Het was altijd erg fijn om tussen de barre 
zoektochten in de vriezers naar samples even een warme kop koffie te komen drinken.
Marion en Margriet,  dank voor al jullie hulp de afgelopen jaren en met name de laatste 
maanden van mijn promotie. Jullie blijven het meest gezellige en vrolijke secretaresse 
duo dat ik ken.
Na een korte tijd met Robert (dankzij jou kwam ik in aanraking met de true science), 
heb ik de langste tijd in Ca-415 op een echte vrouwenkamer gezeten. Edith en Ludi, 
veel hebben we gedeeld op die paar vierkante meter, waar ook nog eens de stoffige 
‘MDL-bieb’ was gevestigd en de temperaturen in de zomer opliepen tot 30 graden. Dank 
voor altijd weer jullie luisterende oor en gezelligheid. Als laatste sloot Esmée zich aan in 
onze gerestylede kamer. Lieve Es, bedankt voor al je support de laatste maanden. 
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Glampa girlz (hepa-chicks), het waren fantastische tijden! Ik heb enorm genoten van alle 
gezellige koffietjes op het dak, etentjes, weekendjes Antwerpen en de vele congressen 
met als hoogtepunten natuurlijk onze camper trip door Californië en onze avonturen in 
NYC! Ook al mijn andere lieve collega-onderzoekers van de dakpoli en het lab en de wis-
selende groep arts-assistenten. Bedankt voor de fijne samenwerkingen, gezellige borrels, 
ski-reisjes en fietsweekendjes. Wat ben ik blij dat ook jullie mijn collega’s van de toekomst 
zijn met hopelijk binnenkort dan toch ook eindelijk een congres met de MDL’ers samen!
Huidige collega’s in het SLAZ: wat hebben jullie me welkom geheten in het Amster-
damse. Ik heb het erg naar mijn zin en kijk uit naar de komende tijd.
Mijn lieve vrienden en vriendinnen van de middelbare school,  uit mijn studententijd, 
bootgenootjes, dispuutgenootjes, (oud-)huisgenootjes en (oud-)teamgenootjes met 
wie ik heerlijk kan eten (die maandagavondetentjes moeten we weer introduceren), 
lachen, borrelen, feesten, sporten, uitgebreid filosoferen of gewoon domweg kletsen 
over van alles en nog wat. Bedankt voor de vele ontspannen momenten  die altijd weer 
heerlijk waren na een dag, week of maand hard werken in het EMC.
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“Lernen Sie ernstnehmen, was des Ernstnehmens wert ist, 
und lachen über das ander“
Hermann Hesse

